Search Result
Results for "
melanoma cancer
" in MedChemExpress (MCE) Product Catalog:
4
Biochemical Assay Reagents
5
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-113107
-
|
|
Endogenous Metabolite
|
Cancer
|
|
3-Hydroxydodecanoic acid is a medium-chain fatty acid. 3-Hydroxydodecanoic acid activates GPR84 and promotes IL-12 production. 3-Hydroxydodecanoic acid has anticancer activity against colon cancer, lung cancer, and melanoma .
|
-
-
- HY-14907
-
|
MPC 6827
|
Microtubule/Tubulin
|
Cancer
|
|
Verubulin (MPC-6827) is a highly potent and broad-spectrum microtubule blocker. Verubulin has antitumor activity against breast cancer, melanoma, and ovarian cancer. Verubulin can be used in non-small cell lung cancer research .
|
-
-
- HY-P99202
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research .
|
-
-
- HY-149950
-
|
|
Apoptosis
|
Cancer
|
|
Anticancer agent 106 (compound 10ic) is an anticancer agent that induces apoptosis in B16-F10 melanoma cells. Anticancer agent 106 also potently inhibits metastatic nodules in a mouse model of lung metastatic melanoma. Anticancer agent 106 can be used in the study of cancer, especially lung metastatic melanoma .
|
-
-
- HY-111575
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
DCB29 is a selective inhibitor of the BPTF bromodomain, with an IC50 value of 13.2 μM. DCB29 can be used for the study of the treatment of BPTF-related diseases (such as bladder cancer, colorectal cancer, melanoma, leukemia, and other cancers) .
|
-
-
- HY-16514
-
|
|
Drug Derivative
|
Cancer
|
|
Vindesine is a semisynthetic derivative of vinblastine. Vindesine is a potent anticancer agent. Vindesine can be used for the research of melanoma and lung cancers .
|
-
-
- HY-176813
-
|
|
LAG-3
|
Cancer
|
|
LAG-3 Hit II is a LAG-3 inhibitor with a KD of 4.32 μM. LAG-3 Hit II can be used for cancers like ovarian cancer, colon adenocarcinoma and melanoma research .
|
-
-
- HY-129144
-
|
|
TNF Receptor
|
Cancer
|
|
Dihydrodehydrodiconiferyl alcohol (compound 2) is a kind of neolignan. Dihydrodehydrodiconiferyl alcohol can be isolated from Anogeissus acuminata. Dihydrodehydrodiconiferyl alcohol has specific cytotoxic activity on melanoma cancer cell line .
|
-
-
- HY-149497
-
|
|
HDAC
|
Cancer
|
|
HDAC6-IN-19 (Compound 14g) is a HDAC6 inhibitor (IC50: 2.68 nM). HDAC6-IN-19 also inhibits HDAC1, HDAC2 and HDAC3 with IC50s of 61.6 nM, 98.7 nM and 103 nM. HDAC6-IN-19 potently inhibits multiple cancer cell proliferation, including leukemia, colon cancer, melanoma, and breast cancer cell lines .
|
-
-
- HY-110350
-
|
|
Haspin Kinase
|
Cancer
|
|
CHR-6494 TFA is a potent inhibitor of haspin, with an IC50 of 2 nM. CHR-6494 TFA inhibits histone H3T3 phosphorylation. CHR-6494 TFA induces the apoptosis of cancer cells, including melanoma and breast cancer. CHR-6494 TFA can be used in the research of cancer .
|
-
-
- HY-150158
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
TMX-201 is a TLR7 ligand-phospholipid conjugate. TMX-201 shows potent immune stimulatory activity. TMX-201 can be used for breast cancer and melanoma research .
|
-
-
- HY-178078
-
|
|
Others
|
Cancer
|
|
PTX-SS-COOH is the proform that can be grafted to the sulfhydryl modified gelatin to form the redox sensitive amphiphilic polymer. The nanoparticle (BSA/Gel-SS-PTX/PTX-SS-COOH NPs) demonstrates an excellent anticancer efficiency. PTX-SS-COOH can be applied in the research of targeted delivery for solid tumors (such as breast cancer and melanoma) by utilizing the unique characteristics of the tumor microenvironment (high GSH level) .
|
-
-
- HY-147574
-
|
|
TAM Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Axl-IN-7 (Chemie 22) is a potent AXL inhibitor. Axl-IN-7 can be used for Axl-related diseases research, for example cancers (such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors), renal disease, immune system disorders, and cardiovascular disease .
|
-
-
- HY-P3742
-
|
|
Tyrosinase
|
Cancer
|
|
Tyrosinase (192-200), human mouse is a nonapeptide. Tyrosinase (192-200), human mouse can be recognized by cytolytic T cell (CTL) on the HLA-B44 molecule. Tyrosinase (192-200), human mouse can be used in research of melanoma associated cancers .
|
-
-
- HY-175034
-
|
|
Topoisomerase
Apoptosis
MDM-2/p53
Bcl-2 Family
Caspase
|
Cancer
|
|
Topoisomerase I/II-IN-1 is a dual inhibitor of topoisomerase I/II. Topoisomerase I/II-IN-1 induces G2/M arrest and apoptosis in cancer cells by upregulating p53, p21, and Bax mRNA levels, caspase-3 protein levels, and the Bax/Bcl-2 ratio, while downregulating Bcl-2. Topoisomerase I/II-IN-1 is useful in the study of various cancers, including melanoma, renal cancer, colorectal cancer, and breast cancer .
|
-
-
- HY-155176
-
|
|
HDAC
|
Cancer
|
|
SP-2-225 is a selective HDAC6 inhibitor. SP-2-225 enhance the production of cancer-associated antigens and macrophage antigen cross-presentation to T cells. SP-2-225 reduces the tumor volume in a syngeneic SM1 melanoma model .
|
-
-
- HY-P99205
-
|
|
ADC Antibody
|
Cancer
|
|
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
|
-
-
- HY-122534
-
|
|
Mitochondrial Metabolism
ADC Payload
Apoptosis
|
Cancer
|
|
Mensacarcin, a highly complex polyketide, strongly inhibits cell growth universally in cancer cell lines and potently induces apoptosis in melanoma cells. Mensacarcin targets to mitochondria, affects energy metabolism in mitochondria, and activates caspase-dependent apoptotic pathways. Mensacarcin, an antibiotic, can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .
|
-
-
- HY-P990106
-
|
|
VEGFR
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse VEGFR-2 Antibody (DC101) is a rat anti-mouse VEGFR2 monoclonal antibody. Anti-Mouse VEGFR-2 Antibody (DC101) inhibits tumor angiogenesis by blocking the binding of VEGF and VEGFR2. Anti-Mouse VEGFR-2 Antibody (DC101) promotes immune cell infiltration and induces tumor cell apoptosis. Anti-Mouse VEGFR-2 Antibody (DC101) can be used for researches on various types of cancer such as melanoma, lung cancer and breast cancer .
|
-
-
- HY-176814
-
|
|
LAG-3
|
Cancer
|
|
LAG-3-IN-1 (Compound 11) is a LAG-3 inhibitor with a KD of 0.41 μM. LAG-3-IN-1 disrupts the LAG-3/MHCII interaction, enhances IFN-γ secretion and promotes tumor cell killing in cocultures of PBMCs and cancer cells. LAG-3-IN-1 can be used for cancers like ovarian cancer, colon adenocarcinoma and melanoma research .
|
-
-
- HY-P990805
-
|
|
HSP
|
Metabolic Disease
Cancer
|
|
Anti-Human/Mouse GRP78 Antibody (C38) is a kind of mouse IgG2b antibody inhibitor, targeting to GRP78. Anti-Human/Mouse GRP78 Antibody (C38) inhibits RhoA, ROCK and AKT activation. Anti-Human/Mouse GRP78 Antibody (C38) can be used for the researches of cancer and metabolic disease, such as melanoma and diabetes .
|
-
-
- HY-175369
-
|
|
PI3K
Akt
PD-1/PD-L1
Interleukin Related
CD3
|
Inflammation/Immunology
Cancer
|
|
PI3Kδ-IN-25 is an orally active selective PI3Kδ inhibitor (IC50 = 2.1 nM). PI3Kδ-IN-25 has IC50s of 272, 285, and 1171 nM for PI3Kα, PI3Kγ, and PI3Kβ, respectively. PI3Kδ-IN-25 inhibits AKT Ser473 phosphorylation, suppresses Treg cell proliferation, and downregulates PD-L1 expression in B16F10 cells. PI3Kδ-IN-25 exhibits anticancer effects in B16F10 melanoma and Lewis lung cancer mouse models by reducing tumor-infiltrating Treg cells and enhancing immune responses. PI3Kδ-IN-25 is potentially useful in the study of melanoma, lung cancer, and other cancers .
|
-
-
- HY-P99132
-
|
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonal antibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances T cell function by increasing the ratio of CD8 + T cells to regulatory T cells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma .
|
-
-
- HY-155522
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
WES-1 (Compound 8g) is an inhibitor of carbonic anhydrase IX (Ki: 55.9 μM). WES-1 has broad spectrum anti-proliferative activity against the cancer cells, such as leukemia (K-562 and MOLT-4), non-small cell lung cancer (NCI–H460), colon cancer (HCT 116 and HCT-15) and melanoma (LOX IMVI) cell lines .
|
-
-
- HY-P991425
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
AT-1413 is a human monoclonal antibody (mAb) targeting CD43. AT-1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. AT-1413 has antitumor activity in AML mouse models. AT-1413 can be used in Acute myeloid leukaemia, Breast cancer, Malignant melanoma and Myelodysplastic syndromes research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
-
- HY-W854934
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
IKP-104 is a microtubule/tubulin inhibitor (IC50 = 1.31 μM). IKP-104 arrests cells in mitosis and the M phase by inhibiting microtubule polymerization and inducing cytoskeletal microtubule depolymerization. IKP-104 inhibits the growth of mouse and human tumor cell lines. IKP-104 exhibits anti-tumor effects in mouse ascites tumors and lung cancer models. IKP-104 is useful in the research of cancers such as leukemia, lung cancer and melanoma .
|
-
-
- HY-172671
-
|
|
STING
|
Cancer
|
|
STING agonist-43 (Compound 67) is a selective STING agonist (EC50: 20.53 μM). STING agonist-43 selectively amplifies cGAMP-dependent STING pathway activation by modulating STING oligomerization. B16.F10 has antitumor activity in a mouse melanoma model. STING agonist-43 can be used for the study of cancer immunity .
|
-
-
- HY-B0078A
-
|
Imidazole Carboxamide citrate
|
Apoptosis
Antibiotic
|
Cancer
|
|
Dacarbazine citrate is a cell cycle nonspecific antineoplastic alkylating agent. Dacarbazine citrate inhibits T and B lymphoblastic response, with IC50 values of 50 and 10 μg/mL, respectively. Dacarbazine Citrate can be used for the research of apoptosis and various cancers such as metastatic malignant melanoma .
|
-
-
- HY-P11110
-
|
|
PD-1/PD-L1
|
Cancer
|
|
RK-10 is a PD-L1 binding peptide. RK-10 conjugated with Cy5 (HY-D0821) or Biotin (HY-B0511) can used to detect PD-L1 expressing tumors with flow cytometry or immunohistochemistry. RK-10 can be used for cancers like NSCLC, breast cancer, squamous cell carcinoma and melanoma detection research .
|
-
-
- HY-121524
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
DJ101 is a potent and metabolically stable tubulin inhibitor. DJ101 targets the colchicine binding site and overcomes taxane resistance. DJ101 also inhibits melanoma tumor growth and lung metastasis. DJ101 can be used for prostate cancer research .
|
-
-
- HY-153863
-
|
|
PROTACs
MEK
Raf
|
Cancer
|
|
MS934 is a novel improved VHL-recruiting MEK 1/2 PROTAC degrader. MS934 also degrades CRAF. MS934 can be used for the research of variety of human cancers, such as melanoma, nonsmall cell lung cancer (NSCLC), colorectal cancer, primary brain tumors, and hepatocellular carcinoma (Pink: Target protein ligand (HY-168288); Black: linker (HY-168289); Blue: E3 ligase ligand (HY-112078)) .
|
-
-
- HY-146245C
-
-
-
- HY-124822
-
COH-SR4
2 Publications Verification
|
AMPK
|
Metabolic Disease
Cancer
|
|
COH-SR4 is an AMPK activator. COH-SR4 shows potent anti-proliferative activities against leukemia, melanoma, breast and lung cancers. COH-SR4 inhibits adipocyte differentiation via AMPK activation. COH-SR4 can be used for the research of obesity and related metabolic disorders .
|
-
-
- HY-117707
-
|
|
Raf
|
Cancer
|
|
EBI-907 is an orally active and highly potent B-Raf V600E inhibitor. EBI-907 demonstrates excellent A375 and Colo-205 cellular antiproliferative activity with IC50 values of 13 nM and 14 nM, respectively. EBI-907 can also cause tumor regression in a B-Raf V600E-dependent Colo-205 tumor xenograft model of mice. EBI-907 is promising for research of melanoma and B-Raf V600E associated cancers .
|
-
-
- HY-154919
-
|
|
YTHDF
FOXO
MMP
Pyroptosis
Interleukin Related
|
Endocrinology
Cancer
|
|
DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (KD: 37.9 μM). DC-Y13-27 inhibits YTHDF2, restores FOXO3 and TIMP1 protein levels, and reduces MMP1/3/7/9 expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer .
|
-
-
- HY-P11018
-
|
|
Peptide-Drug Conjugates (PDCs)
Ephrin Receptor
|
Cancer
|
|
(123B9)2-L2-PTX is an EphA2-agonistic peptide-drug conjugate (PDC). (123B9)2-L2-PTX consists of a dimeric 123B9 (HY-P10579) and Paclitaxel (HY-B0015). (123B9)2-L2-PTX significantly reduces circulating tumor cells and inhibits lung tumor metastasis in breast-cancer-Metastasis mice model. (123B9)2-L2-PTX can be used for cancers research, such as melanomas and ovarian and breast cancers .
|
-
-
- HY-176282
-
|
|
CDK
PI3K
|
Cancer
|
|
CDK8-IN-19 (Compound 3d) is a CDK8 inhibitor with an IC50 of 25.08 nM. CDK8-IN-19 has a broad-spectrum anticancer activity, such as leukemia, melanoma and breast cancer, without significant cytotoxic effect on the normal Vero cells (mean IC50s of 2.87, 3.65, 3.79 and 45.48 μM, respectively) .
|
-
-
- HY-111604
-
|
|
Others
|
Cancer
|
|
Turbinaric acid is a kind of secosqualene carboxylic acid. Turbinaric acid exhibits cytotoxicity against mouse melanoma cells and human colon cancer cells. Turbinaric acid can be used as a chemical marker for T. conoides. Turbinaric acid can be used for research on melanoma and colon cancer .
|
-
-
- HY-124309
-
|
|
Lactate Dehydrogenase
Apoptosis
|
Cancer
|
|
NHI-2 is a lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 14.7 µM. NHI-2 shows selective for LDHA over LDHB (IC50 = 55.8 µM). NHI-2 is an efficient anti-glycolytic agent. NHI-2 enhances apoptosis, induces cell cycle arrest at S and G2 phases. NHI-2 has a broad spectrum anti-proliferative activity in cancer cells. NHI-2 affects extracellular acidification rate and ATP production. NHI-2 suppresses tumor growth in murine B78 melanoma tumor model .
|
-
-
- HY-P991566
-
|
|
CTLA-4
|
Cancer
|
|
KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .
|
-
-
- HY-P990273
-
|
|
CD38
ERK
CD1
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD38 Antibody (NIMR5) is an anti-mouse CD38 IgG2a monoclonal antibody. Anti-Mouse CD38 Antibody (NIMR5) can activate the ERK signaling pathway and promote cell apoptosis. Anti-Mouse CD38 Antibody (NIMR5) can restore T cell function. Anti-Mouse CD38 Antibody (NIMR5) upregulates the expression of CD1d protein and enhances spleen cell proliferation, dendritic cell (DC) and natural killer T cell (NKT) expansion. Anti-Mouse CD38 Antibody (NIMR5) can be used for researches on cancer and immunology such as melanoma and colon cancer .
|
-
-
- HY-P9978
-
|
JS-001
|
PD-1/PD-L1
|
Cancer
|
|
Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .
|
-
-
- HY-139860
-
|
|
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Anticancer agent 15 is capable of significantly increasing the cellular level of ROS and inducing melanoma cancer cell death via necroptosis.
|
-
-
- HY-149949
-
|
|
Apoptosis
|
Cancer
|
|
Anticancer agent 105 is a compound based on thienopyrimidine scaffold, with with good safety and anticancer properties. Anticancer agent 105 shows selective toxicity towards melanoma cancer, and induces apoptosis. And Anticancer agent 105 significantly inhibits the metastatic nodules, even in pulmonary metastatic melanoma mouse model .
|
-
-
- HY-N0610A
-
|
3-Phenylacrylic acid; β-Phenylacrylic acid
|
Endogenous Metabolite
|
Cancer
|
|
Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
|
-
-
- HY-120599A
-
|
VERU-111 hydrochloride; ABI-231 hydrochloride
|
Microtubule/Tubulin
Apoptosis
HPV
Endogenous Metabolite
|
Cancer
|
|
Sabizabulin hydrochloride is a potent orally bioavailable microtubule inhibitor with activity that interacts with the colchicine binding site. Sabizabulin hydrochloride demonstrated significant inhibition of melanoma tumor growth with an average IC50 of 5.2 nM in melanoma and prostate cancer cell lines. Pharmacological screening of Sabizabulin hydrochloride shows it has a low risk of potential side effects .
|
-
-
- HY-123758
-
-
-
- HY-138098
-
|
|
Endogenous Metabolite
|
Cancer
|
|
Sartorypyrone B is a 2β-acetoxyl analogue of chevalone C. Sartorypyrone B is yielded from the ethyl acetate extract of the culture of the marine sponge-associated fungus Neosartorya tsunodae (KUFC 9213). Sartorypyrone B exhibits strong growth inhibitory activity, having GI50s of 17.8, 20.5, and 25.0 μM, respectively, for MCF-7, NCI-H460, and A375-C5. Sartorypyrone B has the potential for the research of breast adenocarcinoma, non-small cell lung cancer, and melanoma diseases .
|
-
-
- HY-156551
-
|
|
Wnt
|
Cancer
|
|
Porcn-IN-2 (Example 107) is a Wnt inhibitor, with an IC50 value of 0.05 nM. Porcn-IN-2 can be used for research of cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia, etc .
|
-
-
- HY-177081
-
|
|
MEK
|
Cancer
|
|
Envometinib (Compound B) is a dual-MEK inhibitor that works through Deep Cyclic Inhibition (DCI). Envometinib has antitumor activity in various in vivo models. Envometinib can be studied in RAS and RAF mutated cancer such as colorectal cancer and melanoma .
|
-
- HY-174837
-
|
|
Topoisomerase
|
Cancer
|
|
Topoisomerase IIα-IN-11 (Compound 16h) is a potent Topoisomerase IIα inhibitor. Topoisomerase IIα-IN-11 shows significant inhibition on melanoma A2058 cell lines (IC50 3-6 μM). Topoisomerase IIα-IN-11 is promising for research of cancers (especially melanoma) .
|
-
- HY-102010
-
|
(+)-Pancratistatin
|
Apoptosis
|
Cancer
|
|
Pancratistatin is an isoquinoline alkaloid that can be isolated from Hymenocallis littoralis. Pancratistatin induces apoptosis of human melanoma cells. Pancratistatin can be used for the research of neuroblastoma, leukemia and breast cancer .
|
-
- HY-146154
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-58 (Compound 4a) is a potent, ATP-competitive, and selective EGFR inhibitor. EGFR-IN-58 shows potent cytotoxicity against melanoma, colon, and blood cancers .
|
-
- HY-N0308
-
|
|
Others
|
Cancer
|
|
Octyl acetate is an orally active aliphatic ester. Octyl acetate has certain antioxidant properties. Octyl acetate contributes to the formation of fruit aroma and affects the flavor of fruits such as strawberries. Octyl acetate can be used in the research of malignant melanoma, colon cancer and breast cancer .
|
-
- HY-177347
-
|
|
Ribosomal S6 Kinase (RSK)
|
Cancer
|
|
RSK2-IN-5 (compoud C2) is a p90 ribosomal S6 kinase 2 (RSK2) inhibitor with a Kd of 856 nM. RSK2-IN-5 exhibits antitumor activity against breast cancer and melanoma cancer cells .
|
-
- HY-119425
-
|
ICRF 159
|
Topoisomerase
|
Cancer
|
|
Razoxane (ICRF 159), a EDTA (HY-Y0682) derivative, is an orally active antiangiogenic topoisomerase II inhibitor. Razoxane has antineoplastic, antiangiogenic, and antimetastatic activities. Razoxanecan be used for the research of renal cell carcinoma (RCC), lung cancer and melanoma cancer .
|
-
- HY-175256
-
|
|
Ribosomal S6 Kinase (RSK)
|
Cancer
|
|
RSK2-IN-5 (compoud C24) is a p90 ribosomal S6 kinase 2 (RSK2) inhibitor with a Kd of 317 nM. RSK2-IN-5 exhibits antitumor activity against breast cancer and melanoma cancer cells .
|
-
- HY-P99049
-
|
APX005M; APX005M; EPI-0050
|
TNF Receptor
|
Inflammation/Immunology
|
|
Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma .
|
-
- HY-108775A
-
|
Sodium hyposulfite (99%, water≤1.0%)
|
Biochemical Assay Reagents
GSK-3
β-catenin
Interleukin Related
COX
NF-κB
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Sodium thiosulfate is an antioxidant. Sodium thiosulfate inhibits the expression of p-GSK-3β and β-catenin proteins, reduces IL-1β, COX-2, and Iba-1, and inhibits NFκB activation. Sodium thiosulfate promotes angiogenesis, inhibits inflammation, and improves acute lung injury. Sodium thiosulfate also exhibits anti-cancer activity against melanoma. Sodium thiosulfate also exerts renal protective effects. Sodium thiosulfate can be used in the research of osteoarthritis, brain inflammation, cancer (such as breast cancer, melanoma), and kidney disease .
|
-
- HY-N0610AS
-
|
3-Phenylacrylic acid-d6; β-Phenylacrylic acid-d6
|
Endogenous Metabolite
|
Cancer
|
|
Cinnamic acid-d6 is the deuterium labeled Cinnamic acid. Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
|
-
- HY-W013386
-
LY83583
1 Publications Verification
|
Guanylate Cyclase
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
LY83583 is inhibitor of soluble guanylate cyclase (sGC) with the ability to target the cGMP signaling pathway. LY83583 inhibits the kinase activity-related proliferation of tumor cells by inducing the Cdk inhibitor p21. LY83583 can be used for the study of cancers (colorectal cancer, breast cancer and melanoma) and cardiovascular disease .
|
-
- HY-151587
-
|
|
Others
|
Cancer
|
|
Anticancer agent 89 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor activity, has high inhibition against the three cell line from ovarian cancer (OVCAR-4), renal cancer (A498), and melanoma (SK-MEL-5) .
|
-
- HY-111898
-
|
|
Others
|
Cancer
|
|
Epirosmanol is a nature diterpene lactone from S. officinalis. Epirosmanol shows anti-cancer activity and inhibits melanin biosynthesis against melanoma cells. Epirosmanol also exhibits DPPH radical scavenging activity .
|
-
- HY-171186
-
|
|
Drug Derivative
|
Cancer
|
|
EAPB0202 is an imidazolium and quinoxaline derivative. EAPB0202 shows significant cytotoxicity to A375 human melanoma cell line with an IC50 of 2.35 μM. EAPB0202 can be used in the study of cancer .
|
-
- HY-164400
-
|
|
MEK
ERK
Akt
Apoptosis
|
Cancer
|
|
SIJ1777 is a GNF-7 (HY-10943) derivative, possesses potent anti-cancer effects on melanoma cells harboring BRAF class I/II/III mutations. SIJ1777 substantially inhibits the activation of MEK, ERK, and AKT. SIJ1777 remarkably induces apoptosis and significantly blocks migration, invasion, and anchorage-independent growth of melanoma cells harboring BRAF class I/II/II mutations .
|
-
- HY-N0610AR
-
|
3-Phenylacrylic acid (Standard); β-Phenylacrylic acid (Standard)
|
Reference Standards
Endogenous Metabolite
|
Cancer
|
|
Cinnamic acid (Standard) is the analytical standard of Cinnamic acid. This product is intended for research and analytical applications. Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
|
-
- HY-100012
-
|
|
Phosphoglycerate Dehydrogenase (PHGDH)
|
Cancer
|
|
CBR-5884 is an active, selective inhibitor of phosphoglycerate dehydrogenase (PHGDH) with an IC50 of 33 μM. CBR-5884 inhibits de novo serine synthesis in cancer cells and is selectively toxic to cancer cell lines with high serine biosynthetic activity. CBR-5884 selectively inhibits the proliferation of melanoma and breast cancer lines that have a high propensity for serine synthesis .
|
-
- HY-162825
-
|
|
Photosensitizer
|
Cancer
|
|
Antitumor photosensitizer-7 (compound 15) is a photosensitizer with anti-cancer activity. Antitumor photosensitizer-7 exhibits significant cytotoxicity against the G361 melanoma cell line under 414 nm blue light irradiation .
|
-
- HY-103317A
-
|
|
Calcium Channel
|
Cardiovascular Disease
Cancer
|
|
NAADP tetrasodium is a second messenger. NAADP tetrasodium releases Ca 2+ from acidic endosomes and lysosomes. NAADP tetrasodium can be used to study cancer (such as oral squamous cell carcinoma, malignant melanoma) and angiogenesis-related diseases .
|
-
- HY-163076
-
|
|
Apoptosis
|
Others
|
|
Anticancer agent 174 (BA-3) is an anticancer agent. Anticancer agent 174 induces tumor cell apoptosis through the mitochondrial pathway. Anticancer agent 174 inhibits cancer cell proliferation in melanoma mouse xenograft model .
|
-
- HY-119261
-
|
|
Antibiotic
|
Cancer
|
|
Ruboxyl is an anthracycline antibiotic with antitumor activity. Ruboxyl inhibits colorectal cancer (CRC) liver metastasis in mice by 84%, suppresses B16 melanoma growth, and increases the survival rate of mice with L1210 or L5178Y leukemia .
|
-
- HY-164473
-
|
|
ERK
Akt
STAT
Apoptosis
|
Cancer
|
|
DETD-35 is an inhibitor of the MEK-ERK, Akt, and STAT3 signaling pathways, which promotes cancer cell apoptosis (Apoptosis) and reduces cancer cell resistance to Vemurafenib (HY-12057). The IC50 values of DETD-35 against wild-type and mutant melanoma cell lines B16-F10, MeWo, SK-MEL-2, A2058c, and A375c are 2.7, 6.0, 3.9, 3.1, and 2.5 μM, respectively. DETD-35 holds promise for research in the field of anti-melanoma therapy .
|
-
- HY-P1585
-
|
Hgp100 (25-33)
|
MHC
|
Cancer
|
|
Gp100 (25-33), human (Hgp100 (25-33)) is the amino acids 25-33 fragment of the human melanoma antigen. Gp100 (25-33), human is a 9-amino acid (AA) epitope restricted by MHC class I H-2D b and recognized by the T cells. Gp100 (25-33), human has immunogenicity and induces specific T cells. Gp100 (25-33), human can be used for the cancer research, such as melanoma .
|
-
- HY-120607
-
|
|
Parasite
|
Infection
Cancer
|
|
Chevalone C, a meroterpenoid fungal metabolite, shows antimalarial activity with IC50 value of 25.00 μg/mL. Chevalone C has anti-proliferative activity on colon HCT116, liver HepG2 and melanoma A375 cancer cell lines .
|
-
- HY-170510
-
|
|
Galectin
|
Cancer
|
|
GB2095 is an orally active and selective galectin-3 inhibitor. GB2095 shows superior selectivity for both human (KD = 0.036 μM) and mouse galectin-3 (KD = 0.35 μM) over other galectins (such as h-Gal-1/4N/4C/8N/8C/9N/9C and m-galectin-1). GB2095 inhibits tumor growth in syngeneic mouse models of breast and melanoma cancers. GB2095 can be used for breast and melanoma cancer research .
|
-
- HY-113107R
-
|
|
Reference Standards
Endogenous Metabolite
|
Metabolic Disease
|
|
3-Hydroxydodecanoic acid (Standard) is an analytical standard for 3-Hydroxydodecanoic acid. This product is intended for use in research and analytical applications. 3-Hydroxydodecanoic acid is a medium-chain fatty acid. 3-Hydroxydodecanoic acid activates GPR84 and promotes IL-12 production. 3-Hydroxydodecanoic acid has anticancer activity against colon cancer, lung cancer, and melanoma .
|
-
- HY-N0308R
-
|
|
Reference Standards
Biochemical Assay Reagents
|
Cancer
|
|
Octyl acetate (Standard) is the analytical standard of Octyl acetate (HY-N0308). This product is intended for research and analytical applications. Octyl acetate is an orally active aliphatic ester. Octyl acetate has certain antioxidant properties. Octyl acetate contributes to the formation of fruit aroma and affects the flavor of fruits such as strawberries. Octyl acetate can be used in the research of malignant melanoma, colon cancer and breast cancer .
|
-
- HY-P1585A
-
|
Hgp100 (25-33) TFA
|
MHC
|
Cancer
|
|
Gp100 (25-33), human TFA (Hgp100 (25-33) (TFA)) is the amino acids 25-33 fragment of the human melanoma antigen. Gp100 (25-33), human TFA is a 9-amino acid (AA) epitope restricted by MHC class I H-2D b and recognized by the T cells. Gp100 (25-33), human TFA has immunogenicity and induces specific T cells. Gp100 (25-33), human TFA can be used for the cancer research, such as melanoma .
|
-
- HY-120599
-
|
VERU-111; ABI-231
|
Microtubule/Tubulin
Apoptosis
HPV
|
Cancer
|
|
VERU-111 (ABI-231) is a potent and orally active α and β tubulin inhibitor, which displays strong antiproliferative activity, with an average IC50 of 5.2 nM against panels of melanoma and prostate cancer cell lines. VERU-111 (ABI-231) suppresses tumor growth and metastatic phenotypes of cervical cancer cells via targeting HPV E6 and E7, and has potential for the treatment of prostate cancer .
|
-
- HY-W013386R
-
|
|
Reference Standards
Guanylate Cyclase
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
LY83583 (Standard) is the analytical standard of LY83583 (HY-W013386). This product is intended for research and analytical applications. LY83583 is inhibitor of soluble guanylate cyclase (sGC) with the ability to target the cGMP signaling pathway. LY83583 inhibits the kinase activity-related proliferation of tumor cells by inducing the Cdk inhibitor p21. LY83583 can be used for the study of cancers (colorectal cancer, breast cancer and melanoma) and cardiovascular disease .
|
-
- HY-147794
-
|
|
CDK
COX
EGFR
|
Cancer
|
|
CDK9-IN-41 is a potent CDK9, EGFR, HER2, and COX-2 kinases inhibitor with IC50s of 192.81 nM, 254.03 nM, 238.81 nM, and 775 nM. COX-2-IN-18 exhibits remarkable antitumor activity against leukemia cancer cells, colon cancer cells, melanoma cells, ovarian cells and breast cells .
|
-
- HY-147855
-
ACA-28
1 Publications Verification
|
ERK
Apoptosis
Reactive Oxygen Species (ROS)
Keap1-Nrf2
|
Cancer
|
|
ACA-28 is a potent ERK MAPK signaling modulator. ACA-28 selectively inhibits cancer cell growth and induces apoptosis. ACA-28 can activate nuclear factor erythroid 2-related factor 2 (Nrf2) signaling via inducing ROS production. ACA-28 can be used for the research of cancer, such as melanoma
.
|
-
- HY-147268
-
|
RAF/KIN_2787
|
Raf
p38 MAPK
|
Cancer
|
|
Exarafenib (RAF/KIN_2787) is an orally-available, selective pan-RAF inhibitor. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. Exarafenib has anticancer activity .
|
-
- HY-12842
-
|
|
IAP
Apoptosis
|
Cancer
|
|
UC-112 is a novel potent IAP(Inhibitor of apoptosis) inhibitor; potently inhibit cell growth in two human melanoma (A375 and M14) and two human prostate (PC-3 and DU145) cancer cell lines(IC50=0.7-3.4 uM).
|
-
- HY-N0610AS2
-
|
3-Phenylacrylic acid-13C3; β-Phenylacrylic acid-13C3
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Cancer
|
|
Cinnamic acid- 13C3 (3-Phenylacrylic acid- 13C3) is the 13C labeled Cinnamic acid (HY-N0610A). Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells .
|
-
- HY-N11644
-
|
|
Others
|
Cancer
|
|
Lanosta-7,9(11),24-trien-3α-hydroxy-26-oic acid, also known as ganoderic acid 24. Lanosta-7,9(11),24-trien-3α-hydroxy-26-oic acid shows high cytotoxicity against cancer cells, such as human lung cancer cells CH27, melanoma cells M21, and oral cancer cells HSC-3 .
|
-
- HY-163828
-
|
|
Apoptosis
Phosphatase
c-Myc
GSK-3
ERK
Reactive Oxygen Species (ROS)
|
Cancer
|
|
PPA24 is a PP2A activator with a KD of 8.465 μM for PP2ACα. PPA24 induces cancer cell death via apoptosis. PP2ACα induces ROS generation and decreases the level of c-Myc expression. PPA24 can be used to study colorectal cancer (CRC), Folinic acid (HY-17556), 5-Fluorouracil (HY-90006), and Oxaliplatin (HY-17371) (FOLFOX)-resistant CRC, and melanoma cancer .
|
-
- HY-175039
-
|
|
FAK
Apoptosis
Reactive Oxygen Species (ROS)
Caspase
|
Cancer
|
|
FAK-IN-28 is an orally active FAK inhibitor (IC50 = 0.4 nM). FAK-IN-28 exhibits dual antiproliferative and anti-metastatic properties. FAK-IN-28 triggers caspase-3-dependent apoptosis via ROS elevation. FAK-IN-28 inhibits tumor growth without causing weight loss or hepatotoxicity. FAK-IN-28 is useful in the study of FAK-driven malignancies, such as colon cancer, cervical cancer, triple-negative breast cancer, and melanoma .
|
-
- HY-115885
-
|
|
HDAC
|
Inflammation/Immunology
Cancer
|
|
XP5 is a potent, orally active HDAC6 inhibitor with an IC50 of 31 nM. XP5 displays high antiproliferative activity against various cancer cell lines including the HDACi-resistant YCC3/7 gastric cancer cells (IC50=0.16-2.31 μM). XP5 enhances antitumor immunity when combined with a PD-L1 inhibitor in melanoma .
|
-
- HY-163136A
-
|
|
Autophagy
REV-ERB
|
Cancer
|
|
Autophagy/REV-ERB-IN-1
hydrochloride (Compound 24) is a dual autophagy and REV-ERB inhibitor with
anticancer activity. Autophagy/REV-ERB-IN-1 (hydrochloride) has improved
potency in blocking autophagy, enhanced toxicity against cancer cells.
Autophagy/REV-ERB-IN-1 (hydrochloride) can be used for the research for
melanoma .
|
-
- HY-P10010
-
|
|
Galectin
|
Cancer
|
|
DB21, Galectin-1 Antagonist is a dibenzofuran conjugated peptidomimetic that acts as an allosteric inhibitor of galectin-1 (GAL1)binding to cell surface glycans. DB21, Galectin-1 Antagonis increases inhibition of angiogenesis and tumour growth in melanoma, lung adenocarcinoma and ovarian cancer models .
|
-
- HY-N0421
-
|
Cinobufagine
|
Apoptosis
|
Neurological Disease
Cancer
|
|
Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models .
|
-
- HY-N0288
-
|
|
Fatty Acid Synthase (FASN)
Virus Protease
Bacterial
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Lycorine is a natural alkaloid extracted from the Amaryllidaceae plant. Lycorine is a potent and orally active SCAP inhibitor with a Kd value 15.24 nM. Lycorine downregulates the SCAP protein level without changing its transcription . Lycorine is also a melanoma vasculogenic inhibitor . Lycorine can be used for the study of prostate cancer and metabolic diseases .
|
-
- HY-163595
-
|
|
Ras
|
Cancer
|
|
KRAS G12D-IN-31 is a potent KRAS G12D inhibitor with an IC50 of < 100 nM. KRAS G12D-IN-31 inhibits the proliferation of RAS-dependent cells (KRAS G12C, KRAS G12D, KRAS G12V and KRAS WT). KRAS G12D-IN-31 can be used to study non-small cell lung cancer, gastric cancer, colon cancer, and malignant melanoma .
|
-
- HY-W231513
-
|
|
MASTL
Ser/Thr Protease
Aurora Kinase
|
Cancer
|
|
MASTL/Aurora A-IN-1 (Compound MA4) is a dual inhibitor of MASTL and Aurora A kinases with IC50 values of 0.56 μM and 0.16 μM, respectively. MASTL/Aurora A-IN-1 has broad-spectrum anticancer activity and has potent anticancer activity against SR (leukemia), K-562 (leukemia), MDA-MB-435 (melanoma), MOLT-4 (leukemia), and SK-MEL-2 (melanoma) cell lines in NCI-60 cancer cell lines with GI50 values of 0.023, 0.032, 0.037, 0.044, and 0.051 μM, respectively. MASTL/Aurora A-IN-1 inhibits Aurora A and MASTL kinases, inducing cell cycle G2/M arrest, thereby inhibiting cancer cell proliferation. MASTL/Aurora A-IN-1 can be used in cancer research, especially for tumors with dysregulated mitosis .
|
-
- HY-172111
-
|
|
EGFR
Microtubule/Tubulin
Interleukin Related
TNF Receptor
Apoptosis
|
Cancer
|
|
EGFR-IN-144 (Compound 4B) exhibits inhibitory activities against EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). EGFR-IN-144 exhibits cytotoxicity in multiple cancer cell with GI50 of nanomolare levels. EGFR-IN-144 downregulates the expressions of mTOR, TNF-α, and IL-6, arrests the cell cycle at G1/S phase, and induces apoptosis .
|
-
- HY-101087
-
|
|
Carbonic Anhydrase
Amyloid-β
Reactive Oxygen Species (ROS)
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Benzenesulphonamide (Compound 1) is a carbonic anhydrase inhibitor. Benzenesulphonamide exhibits CA II inhibitory activity. Benzenesulphonamide reduces ROS and improves the gene expression of amyloid-β40 and 42. Benzenesulphonamide is beneficial for Alzheimer's disease. Benzenesulphonamide derivatives have anticancer, anti-inflammatory, and anticonvulsant activities. Benzenesulphonamide can be used in the research of Alzheimer's disease, epilepsy, inflammatory diseases, leukemia, melanoma, lung cancer, and colon cancer .
|
-
- HY-P9986
-
|
MTIG-7192A; RG-6058
|
CD28
|
Cancer
|
|
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma .
|
-
- HY-13591
-
|
IB-MECA; CF-101
|
Adenosine Receptor
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Piclidenoson (IB-MECA) is a first-in-class, orally active and selective A3 adenosine receptor (A3AR) agonist. Piclidenoson exhibits antiproliferative effect and induces apoptosis in different cancer cell types like melanoma, leukemia. Piclidenoson can be used for the research of autoimmune inflammatory diseases and COVID-19 .
|
-
- HY-147734
-
|
|
Calcium Channel
|
Cancer
|
|
Calpain Inhibitor-2 (compound 5) is a peptide inhibitor of μ-calpain (Ki=9 nM). Calpain Inhibitor-2 exhibits antiproliferative activity against melanoma cell lines (A-375 and B-16F1) and PC-3 prostate cancer cells in vitro .
|
-
- HY-144898
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
SB-216 is an BBB-penetrable tubulin polymerization inhibitor. SB-216 can inhibit the proliferation and migration, and induce apoptosis and cell cycle arrest of tumor cells. SB-216 has good in vivo metabolic stability and low toxicity, but its oral bioavailability is limited. SB-216 has antitumor activity and can be used in the research of tumors such as melanoma .
|
-
- HY-106435
-
|
|
DNA/RNA Synthesis
DNA Alkylator/Crosslinker
|
Cancer
|
|
Cystemustine is a DNA inhibitor (a chloroethyl nitrosourea, CENU). Cystemustine can cause DNA cross-linking, thereby inhibiting the proliferation of tumor cells. Cystemustine can also exert cytotoxic effects by interfering with the cell cycle, inducing cell re-differentiation, and altering phospholipid metabolism. Cystemustine exhibits high anti-tumor activity and a relatively short plasma half-life in mice. Cystemustine can be used for the study of various malignant tumors, including melanoma, glioma, renal cancer, head and neck cancer, and colorectal cancer, etc .
|
-
- HY-173178
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
LNS8801 is an orally active agonist of the G protein-coupled estrogen receptor (GPER). By activating GPER, LNS8801 mediates downstream signaling pathways, such as promoting the production of cyclic adenosine monophosphate (cAMP) and activating the cAMP response element-binding protein (CREB) signaling, thereby exerting anti-tumor activities including inhibiting tumor cell proliferation, inducing cell differentiation, and enhancing tumor immunogenicity. LNS8801 can be used in the research of various cancers (e.g., melanoma, pancreatic cancer, colorectal cancer, lung cancer, etc.) and relevant studies exploring the roles of GPER in normal physiological and pathological processes .
|
-
- HY-146245
-
-
- HY-N12834
-
|
|
Others
|
Inflammation/Immunology
Cancer
|
|
Ecdysoside B (compound 6b) is a pregnanoside compound isolated from the plant Ecdysanthera rosea. Ecdysoside B and its derivatives and isomers shows anticancer, immunosuppressive and anti-inflammatory activities. Ecdysoside B shows cytotoxicity to a variety of human tumor cell lines, including PANC-1 (human pancreatic cancer cells), A375 (human melanoma cells) and U87 (brain glioma U87 cells). Ecdysoside B can be used for research in the areas of cancer, immunomodulation and anti-inflammato .
|
-
- HY-134920
-
|
|
Indoleamine 2,3-Dioxygenase (IDO)
Apoptosis
SWI/SNF Complex
|
Cancer
|
|
LW106 is a selective IDO1 inhibitor with an IC50 of 1.57 μM. LW106 has no inhibitory effect on IDO2 and TDO. LW106 inhibits tumor outgrowth by limiting stroma-immune crosstalk and CSC enrichment in the tumor microenvironment. LW106 reduces subpopulation of cancer stem cells (CSCs) in xenografted tumors in which less proliferative/invasive tumor cells and more tumor cells apoptosis. LW106 can be used for the studies of lung cancer and melanoma .
|
-
- HY-118487
-
OB-24
1 Publications Verification
|
Heme Oxygenase (HO)
Reactive Oxygen Species (ROS)
|
Cancer
|
|
OB-24 is a selective small-molecule HO-1 inhibitor (IC50 = 1.9 μM for HO-1 and IC50 for HO-2 >100 μM). OB-24 possesses anti-tumor and anti-metastatic properties. OB-24 can be studies in research such as prostate cancer, melanoma, ovarian carcinoma and lung metastasis .
|
-
- HY-152479
-
|
|
Topoisomerase
|
Cancer
|
|
Topoisomerase IIα-IN-7 is an DNA topoisomerase IIα inhibitor with an IC50 value of 7.7 µM. Topoisomerase IIα-IN-7 has broad-spectrum cytotoxicity to leukemia, lung, colon, melanoma, ovarian, kidney, prostate and breast cancer cells. Topoisomerase IIα-IN-7 has metabolic stability .
|
-
- HY-155240
-
|
|
Tyrosinase
|
Cancer
|
|
Tyrosinase-IN-13 (compound 3c), a derivative of Flurbiprofen (HY-10582), is a potent, non-competitive tyrosinase inhibitor (IC50=68 μM; Ki=36.3 μM). Tyrosinase-IN-13 is cytotoxic against hepatocellular carcinoma (HepG2), colorectal cancer (HT-29), and melanoma (B16F10) .
|
-
- HY-18957C
-
|
BGB-283 hydrochloride
|
Endogenous Metabolite
|
Cancer
|
|
Lifirafenib hydrochloride (BGB-283 hydrochloride) is a novel, reversible B-RAFV600E inhibitor with antitumor activity. Lifirafenib has shown potent antitumor activity against solid tumors with B-RAFV600E mutations, such as melanoma, thyroid cancer, and low-grade serous ovarian cancer. Lifirafenib exhibits selective cytotoxicity in vitro, preferentially inhibiting the proliferation of cancer cells with B-RAFV600E and EGFR mutations/amplification. Lifirafenib can achieve dose-dependent inhibition of tumor growth in animal models, accompanied by partial and complete tumor shrinkage .
|
-
- HY-P99101
-
|
AEX-4089; MGC026 antibody
|
ADC Antibody
|
Cancer
|
|
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .
|
-
- HY-149519
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BRD4 Inhibitor-28 (Compound 18) is an orally active BRD4 Inhibitor. BRD4 Inhibitor-28 inhibits BRD40-BD1, BRD40-BD2 with IC50s of 15, 55 nM. BRD4 Inhibitor-28 also inhibits BRD2-BD1, BRD3-BD1, BRDT-BD1 with IC50s of 19, 25, 68 nM. BRD4 Inhibitor-28 has anti-melanoma activity .
|
-
- HY-149471
-
|
|
Tyrosinase
|
Cancer
|
|
hTYR/AbTYR-IN-1 (Compound 7) is a hTYR/AbTYR dual inhibitor, with IC50s of 5.4 μM and 3.52 μM for hTYR and AbTYR respectively .
|
-
- HY-N8207
-
|
|
Apoptosis
MicroRNA
|
Cancer
|
|
Gypenoside LI, a gypenoside monomer, possesses anti-tumor activity. Gypenoside LI induces cell apoptosis, cell cycle and migration .
|
-
- HY-W1126504
-
|
|
Notch
|
Cancer
|
|
ETN029 is a DLL3 ligand. ETN029 labeled with 225Ac has dose-dependent cytotoxicity in SCLC, NEPC and metastatic melanoma cells and increases the phosphorylation of H2AX expression. ETN029 labeled with 177Lu shows rapid uptake persistent tumor retention and favorable tumor-to-kidney ratio. ETN029 can be used for cancers like SCLC and NEPC imaging and research .
|
-
- HY-N0421R
-
|
Cinobufagine (Standard)
|
Reference Standards
Apoptosis
|
Neurological Disease
Cancer
|
|
Cinobufagin (Standard) is the analytical standard of Cinobufagin. This product is intended for research and analytical applications. Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models .
|
-
- HY-N0288R
-
|
|
Fatty Acid Synthase (FASN)
Virus Protease
Bacterial
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Lycorine (Standard) is the analytical standard of Lycorine. This product is intended for research and analytical applications. Lycorine is a natural alkaloid extracted from the Amaryllidaceae plant. Lycorine is a potent and orally active SCAP inhibitor with a Kd value 15.24 nM. Lycorine downregulates the SCAP protein level without changing its transcription . Lycorine is also a melanoma vasculogenic inhibitor . Lycorine can be used for the study of prostate cancer and metabolic diseases .
|
-
- HY-W747797
-
|
|
Isotope-Labeled Compounds
Apoptosis
|
Cancer
|
|
Cinobufagine-d3 is the deuterium labeled Cinobufagin (HY-N0421). Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models .
|
-
- HY-153425
-
|
|
PROTACs
|
Cancer
|
|
PROTAC SMARCA2 degrader-2 is a potent and selective SMARCA2/4 PROTAC degrader with an IC50 of <0.1 μΜ in HeLa HiBiT assay. PROTAC SMARCA2 degrader-2 is extracted from patent WO2023287787A1 and has the potential for SMARCA4-related or deficient cancer research .
|
-
- HY-173149
-
|
|
Anaplastic lymphoma kinase (ALK)
TGF-beta/Smad
TGF-β Receptor
|
Cancer
|
|
CDD-2789 is a highly selective small-molecule inhibitor targeting Activin receptor type 1 (ALK2, also known as ACVR1). It blocks the SMAD1/5 signaling pathway mediated by ALK2/ALK1, thereby effectively suppressing downstream phosphorylation events induced by BMP and activin A. In the NanoBRET cellular model, CDD-2789 exhibits an inhibitory IC50 of 0.54 µM against ALK2. CDD-2789 holds promise for research on ALK2-related diseases, including diffuse intrinsic pontine glioma (DIPG), ependymoma, endometrial cancer, melanoma, non–small cell lung cancer, colorectal cancer, and pancreatic cancer .
|
-
- HY-15150G
-
|
R428 (GMP); BGB324 (GMP)
|
TAM Receptor
|
Cancer
|
|
Bemcentinib (R428) GMP is Bemcentinib (HY-15150) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy.Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .
|
-
- HY-119272
-
EF24
2 Publications Verification
|
ERK
Caspase
NF-κB
Apoptosis
p38 MAPK
Reactive Oxygen Species (ROS)
|
Inflammation/Immunology
Cancer
|
|
EF24, a curcumin analogue, is an NF-kB inhibitor with great anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 is active against melanoma and breast cancer cell lines with GI50 values of 0.7 μM and 0.8 μM, respectively. EF24 induces cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells and DU-145 human prostate cancer cells. EF24 increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK .
|
-
- HY-161778
-
|
|
HDAC
VD/VDR
|
Inflammation/Immunology
Cancer
|
|
ZG-126 is an agonist for vitamin D receptor (VDR) and an inhibitor for histone deacetylase (HDAC) (IC50=0.63-67.6 μM). ZG-126 exhibits cytotoxicity in cancer cells MDA-MB-231 and 4T1. ZG-126 exhibits antitumor and anti-metastatic efficacy against melanoma and triple-negative breast cancer (TNBC) in mouse models. ZG-126 also exhibits anti-inflammatory activity, through the reduction of macrophage infiltration and immunosuppressive M2-polarization .
|
-
- HY-101087R
-
|
|
Reference Standards
Carbonic Anhydrase
Amyloid-β
Reactive Oxygen Species (ROS)
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Benzenesulphonamide (Standard) is the analytical standard of Benzenesulphonamide (HY-101087). This product is intended for research and analytical applications. Benzenesulphonamide (Compound 1) is a carbonic anhydrase inhibitor. Benzenesulphonamide exhibits CA II inhibitory activity. Benzenesulphonamide reduces ROS and improves the gene expression of amyloid-β40 and 42. Benzenesulphonamide is beneficial for Alzheimer's disease. Benzenesulphonamide derivatives have anticancer, anti-inflammatory, and anticonvulsant activities. Benzenesulphonamide can be used in the research of Alzheimer's disease, epilepsy, inflammatory diseases, leukemia, melanoma, lung cancer, and colon cancer .
|
-
- HY-P990861
-
|
|
Transmembrane Glycoprotein
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-CD4 Antibody (OKT-4) is a kind of mouse IgG2b κ chimeric antibody inhibitor, targeting to human CD4. Anti-CD4 Antibody (OKT-4) can deplete T cells. Anti-CD4 Antibody (OKT-4) can be used for the researches of cancer, infection and immunology, such as melanoma and adenovirus infection .
|
-
- HY-P991243
-
|
|
EGFR
PI3K
Akt
|
Cancer
|
|
MP-RM-1 is a selective murine monoclonal antibody inhibitor targeting human epidermal growth factor receptor 3 (ErbB-3). MP-RM-1 blocks the activation of ErbB-3 induced by neuregulin 1 (NRG-1β) and promotes the internalization and degradation of ErbB-3, inhibiting downstream signaling pathways such as PI3K-Akt. MP-RM-1 is promising for research of ErbB-3 highly expressed solid tumors such as breast cancer, melanoma, and prostate cancer .
|
-
- HY-150510A
-
|
|
Histone Methyltransferase
|
Neurological Disease
Cancer
|
|
MS8511 (hydrochloride) is a selective G9a/GLP covalent irreversible inhibitor by targeting a cysteine residue at the substrate binding site, with IC50 values of 100 nM (G9a) and 140 nM (GLP), and Kd values of 44 nM (G9a) and 46 nM (GLP). MS8511 (hydrochloride) reduces the cellular H3K9me2 level and enhances antiproliferation activity. MS8511 (hydrochloride) can be used for the research of several types of cancers including brain, breast, ovarian, lung, bladder, melanoma, colorectal cancer, and other disease such as Alzheimer’s disease (AD), sickle cell disease, Prader−Willi syndrome (PWS) .
|
-
- HY-150510
-
|
|
Histone Methyltransferase
|
Neurological Disease
Cancer
|
|
MS8511 is a selective G9a/GLP covalent irreversible inhibitor by targeting a cysteine residue at the substrate binding site, with IC50 values of 100 nM (G9a) and 140 nM (GLP), and Kd values of 44 nM (G9a) and 46 nM (GLP). MS8511 reduces the cellular H3K9me2 level and enhances antiproliferation activity. MS8511 can be used for the research of several types of cancers including brain, breast, ovarian, lung, bladder, melanoma, colorectal cancer, and other disease such as Alzheimer’s disease (AD), sickle cell disease, Prader−Willi syndrome (PWS) .
|
-
- HY-176859
-
|
|
Apoptosis
|
Cancer
|
|
[Ru(dpp)(bpy)(mtmp)](PF6)2 (Compound 5) is a trisheteroleptic ruthenium complex. [Ru(dpp)(bpy)(mtmp)](PF6)2 has a light-activated anticancer activity. [Ru(dpp)(bpy)(mtmp)](PF6)2 can selectively cleave off upon green light irradiation, thereby releasing a phototoxic ruthenium-based photoproduct that binds to nuclear DNA, induces DNA damage and apoptosis in cancer cells. [Ru(dpp)(bpy)(mtmp)](PF6)2 can be used for phototherapy of cancers like conjunctival melanoma research .
|
-
2](//file.medchemexpress.eu/product_pic/hy-176859.gif)
- HY-P99291
-
|
LM609; MEDI-522
|
Integrin
Apoptosis
Akt
|
Cancer
|
|
Etaracizumab (LM 609) is an αvβ3 integrin IgG mAb. Etaracizumab is developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofαvβ3-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-176219
-
|
|
Bcl-2 Family
Apoptosis
Necroptosis
|
Cancer
|
|
Bcl-2-IN-23 (compound 5) is a selective inhibitor targeting Bcl-2. The IC50 of Bcl-2-IN-23 in HTB-140, HeLa and SW620 cells is 25.7-33.7 μM. Bcl-2-IN-23 can non-covalently competitively bind to Bcl-2 protein, significantly reduce its expression, and induce late apoptosis and necroptosis of cancer cells. Bcl-2-IN-23 enhances the sensitivity of cancer cells to apoptosis and reduces the release of IL-6 inflammatory factors by disrupting the Bcl-2-mediated mitochondrial apoptosis inhibition pathway. Bcl-2-IN-23 can be used for anti-apoptosis research of malignant tumors such as melanoma, cervical cancer, and colorectal cancer .
|
-
- HY-175867
-
|
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
|
PROTAC SMARCA2 degrader-34 (compound 52) is a selective SMARCA2 PROTAC degrader (DC50 in HeLa cell: < 0.1 μM for SMARCA2, > 1 μM for SMARCA4). PROTAC SMARCA2 degrader-34 can be used for study of cancer. (Pink: SMARCA2 ligand (HY-178414) ; Blue: E3 ligand (HY-168055) ; Black: linker) .
|
-
- HY-W053583
-
|
DOTA
|
Biochemical Assay Reagents
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .
|
-
- HY-117037
-
|
|
Apoptosis
ERK
|
Cardiovascular Disease
Cancer
|
|
FR900359 is a depsipeptide selective inhibitor of Gαq/11/14 in mammalia, can inhibits ERK pathway. FR900359 suppresses the proliferation of melanoma cells and decreases of blood pressure. FR900359 also protected against airway hyperreactivity in murine models of allergen sensitization in Ovalbumins(HY-W250978)–induced sensitization model of asthma. FR900359 can be used for cancer and cardiovascular disease research .
|
-
- HY-175245
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCA-IN-1 (Compound 5u) is an hCA inhibitor with Ki values of 159.2, 4.8, 15.5, and 2 nM against hCA I, hCA II, hCA IX, and hCA XII, respectively. hCA-IN-1 exhibits broad-spectrum anticancer activity against melanoma, breast, and colon cancer cells. ADME predictions indicate that hCA-IN-1 has good solubility and oral bioavailability. hCA-IN-1 can be used in tumor research .
|
-
- HY-N2466
-
|
MT-I; [Nle4,D-Phe7]-α-MSH
|
Melanocortin Receptor
|
Neurological Disease
Cancer
|
|
Melanotan I is a potent non-selective melanocortin receptor (MCR) agonist. Melanotan I is a synthetic analogue of α-melanocyte stimulating hormone (α-MSH) that stimulates melanogenesis. Melanotan I can induce skin tanning by mimicking the actions of a-MSH on the melanocortin type 1 receptors (MC1R) of melanocytes. Melanotan I can be used for the research of sun-induced skin cancer, melanoma, inflammation and male erectile dysfunction .
|
-
- HY-W494890
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
SMARCA2-IN-10 (Compound 4) is a highly selective SMARCA2 ATPase domain inhibitor (IC50=17.676 μM). SMARCA2-IN-10 induces cell death in SMARCA4-deficient tumors. SMARCA2-IN-10 is promising for research of SMARCA4-mutant non-small cell lung cancer, small cell ovarian carcinoma, and melanoma .
|
-
- HY-132844
-
|
HL-085
|
MEK
|
Cancer
|
|
Tunlametinib is a highly selective, orally active MEK1/2 inhibitor (IC50=1.9 nM, MEK1). Tunlametinib blocks the RAS-RAF-MEK-ERK signaling pathway, arrests tumor cell cycle and promotes apoptosis. Tunlametinib potently inhibits the proliferation of RAS/RAF mutant cancer cells (such as BRAF V600E, KRAS G12C mutant cells). Tunlametinib shows synergistic anti-tumor effects with BRAF/KRAS G12C/SHP2 inhibitors, Docetaxel (HY-B0011). Tunlametinib can be used to study targeted therapy for RAS/RAF mutation-driven malignancies (such as melanoma, colorectal cancer, and non-small cell lung cancer) .
|
-
- HY-109582R
-
|
|
Apoptosis
FAK
|
Cancer
|
|
ADT-OH (Standard) is the analytical standard of ADT-OH. This product is intended for research and analytical applications. ADT-OH is a hydrogen sulfide-releasing donor. ADT-OH induces apoptosis and upregulates FADD. ADT-OH inhibits FAK/Paxillin. ADT-OH has the potential for the research of cancer diseases .
|
-
- HY-109582
-
ADT-OH
4 Publications Verification
5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione; ACS 1
|
Apoptosis
FAK
|
Cancer
|
|
ADT-OH is a hydrogen sulfide-releasing donor. ADT-OH induces apoptosis and upregulates FADD. ADT-OH inhibits FAK/Paxillin. ADT-OH has the potential for the research of cancer diseases .
|
-
- HY-157800
-
|
TRX-E-009-1
|
Microtubule/Tubulin
Apoptosis
PARP
Caspase
|
Cancer
|
|
Trilexium (TRX-E-009-1) is a third-generation of benzopyran structurally related to TRX-E-002-1 (HY-114250). Trilexium increases p21 protein expression and induces apoptosis. Trilexium depolymerizes microtubules. Trilexium shows broad anti-cancer activity .
|
-
- HY-138799A
-
|
|
HDAC
|
Inflammation/Immunology
Cancer
|
|
KA2507 hydrochloride is a potent and highly selective inhibitor of HDAC6 (IC50=2.5 nM) with no significant toxicities. KA2507 hydrochloride shows antitumor efficacy and immune modulatory effects .
|
-
- HY-138799
-
|
|
HDAC
|
Cancer
|
|
KA2507 is a potent, orally active and selective HDAC6 inhibitor, with an IC50 of 2.5 nM. KA2507 shows antitumor activities and immune modulatory effects in preclinical models .
|
-
- HY-120454
-
|
|
MEK
Potassium Channel
|
Cancer
|
|
G-479 is the inhibitor for MEK and hERG channel (IC50=14 μM). G-479 inhibits the proliferation of HCT-116 and A375 with IC50 of 0.049 μM and 0.004 μM. G-479 exhibits good metabolic stability in liver microsomes and good pharmacokinetic characteristics in rats .
|
-
- HY-149523
-
|
|
Apoptosis
NO Synthase
Caspase
|
Inflammation/Immunology
Cancer
|
|
Anticancer agent 157 (compound 15) is a NO inhibitor (IC50=0.62 μg/mL) with anti-inflammatory and anticancer activities. Anticancer agent 157 can bind to iNOS (inducible NO synthase) and caspase 8, causing nuclear fragmentation and chromatin condensation, inducing apoptosis. Anticancer agent 157 inhibits HT29 colon cancer cells (IC50=2.45 μg/mL), Hep-G2 liver cancer cells (IC50=3.25 μg/mL), and B16-F10 murine melanoma cells (IC50=3.84 μg/mL) .
|
-
- HY-144896
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
FHT-1015 is a selective SMARCA4 (IC50 = 4 nM) and SMARCA2 (IC50 = 5 nM) (also known as BRG1 and BRM) inhibitor. FH-1015 is an allosteric inhibitor that causes conformation change in the BRG1/BRM protein upon interaction with an allosteric site, inhibiting ATPase activity. FH-1015 interferes with tumor cell growth and migration. FH-1015 can be studied in research for uveal melanoma and hematologic cancer .
|
-
- HY-175370
-
|
|
PROTACs
RIP kinase
|
Cancer
|
|
PROTAC RIPK1 Degrader-1 is a selective RIPK1 PROTAC degrader. PROTAC RIPK1 Degrader-1 degrades RIPK1 in multiple cancer cell lines (e.g., A375, B16F10 cells). PROTAC RIPK1 Degrader-1 enhances the anti-cancer effect of radiotherapy in syngeneic and humanized mouse models. PROTAC RIPK1 Degrader-1 can be used to study cancers such as melanoma. (Pink: RIPK1-ligand-2: HY-175371, Blue: (S,R,S)-AHPC-Me: HY-112078, Pink + Black: RIPK1 ligand-Linker Conjugate-1: HY-175374, Black: Bispiperidin-piperazin-acetater: HY-175373) .
|
-
- HY-175298
-
|
|
STAT
Src
Apoptosis
|
Cancer
|
|
STAT-3/c-Src-IN-1 (Compound 12d) is a dual STAT-3 (IC50=0.844 μM) and c-Src (IC50=0.268 μM) inhibitor. STAT-3/c-Src-IN-1 blocks tumor cell proliferation, migration, and angiogenesis signaling pathways. STAT-3/c-Src-IN-1 exhibits potent anti-proliferative activity against melanoma (SK-MEL-2) and CNS cancer (SNB-75) cell lines (GI50=-5.75 μM and -5.63 μM), inducing tumor cell apoptosis via G0/G1 and G2/M phase cell cycle arrest. STAT-3/c-Src-IN-1 is promising for research of melanoma and glioblastoma .
|
-
- HY-P11011
-
|
Pep R54; CXCR4 antagonist peptide 19
|
CXCR
|
Cancer
|
|
Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting CXCR4 with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC50=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .
|
-
- HY-P990165
-
|
|
RANKL/RANK
E1/E2/E3 Enzyme
NF-κB
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse RANKL/CD254 Antibody (IK22/5) is an anti-mouse RANKL/CD254 IgG2a monoclonal antibody. Anti-Mouse RANKL/CD254 Antibody (IK22/5) inhibits osteoclast formation and activity by specifically blocking the binding of RANKL and RANK. Anti-Mouse RANKL/CD254 Antibody (IK22/5) can inhibit the expression of MuRF1/Trogin-1 and activation of NF-κB. Anti-Mouse RANKL/CD254 Antibody (IK22/5) can be used for research on cancer such as melanoma or colon cancer and osteoporosis .
|
-
- HY-168632
-
|
|
Topoisomerase
Apoptosis
|
Cancer
|
|
Topoisomerase I/II inhibitor 6 (compound 3i) is a potent inhibitor of topoisomerase I and II with IC50s of 4.77 and 15 µM, respectively. Topoisomerase I/II inhibitor 6 shows antiproliferative activities against human melanoma LOX IMVI cancer cell line with IC50 values of 26.7 and 25.4 µM, respectively. Topoisomerase I/II inhibitor 6 provokes substantial levels of early, late apoptosis and increases the expression level of active caspase-3 .
|
-
- HY-W587938
-
|
(+)-γ-Eudesmol
|
Apoptosis
|
Cancer
|
|
γ-Eudesmol ((+)-γ-Eudesmol) is a mitochondrial-mediated apoptosis inducer. γ-Eudesmol binds mitochondrial membrane proteins, triggering depolarization of mitochondrial membrane potential and activating caspase cascades. γ-Eudesmol demonstrates cytotoxicity against multiple tumor cell lines (e.g., HepG2, B16-F10) with IC50 values ranging from 8.86-15.15 μg/mL. γ-Eudesmol is promising for research of cancers, such as hepatocellular carcinoma and melanoma .
|
-
- HY-P99781
-
|
MLN-1202
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab can also improve synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-164387A
-
|
|
EGFR
VEGFR
PDGFR
|
Cancer
|
|
Sutetinib maleate is the maleate form of Sutetinib (HY-164387). Sutetinib maleate is an orally active inhibitor for tyrosine kinase, that is associated with tumor growth and angiogenesis, such as VEGFR (Ki= 0.009 µM for VEGFR-1/2/3), PDGFR (Ki= 0.008 µM for PDGFR-α/β) and proto-oncogene cKIT. Sutetinib maleate inhibits the proliferation, migration, and tubular structure formation of endothelial cells and fibroblasts, and exhibits board-spectrum antitumor efficacy in vitro and in vivo .
|
-
- HY-164387
-
|
|
EGFR
PDGFR
VEGFR
|
Cancer
|
|
Sutetinib is an orally active inhibitor for tyrosine kinase, that is associated with tumor growth and angiogenesis, such as VEGFR (Ki= 0.009 µM for VEGFR-1/2/3), PDGFR (Ki= 0.008 µM for PDGFR-α/β) and proto-oncogene cKIT. Sutetinib inhibits the proliferation, migration, and tubular structure formation of endothelial cells and fibroblasts, and exhibits board-spectrum antitumor efficacy in vitro and in vivo .
|
-
- HY-134463
-
|
|
Epigenetic Reader Domain
Apoptosis
|
Cancer
|
|
NHWD-870 is a potent, orally active and selective BET family bromodomain inhibitor and only binds bromodomains of BRD2, BRD3, BRD4 (IC50=2.7 nM), and BRDT. NHWD-870 has potent tumor suppressive efficacies and suppresses cancer cell-macrophage interaction. NHWD-870 increases tumor apoptosis and inhibits tumor proliferation .
|
-
- HY-P990149
-
|
|
Tyrosinase
|
Cancer
|
|
Anti-Mouse/Human TYRP1 Antibody (TA99) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse/human TYRP1. Anti-Mouse/Human TYRP1 Antibody (TA99) binds to Tyrp1 (tyrosinase related protein-1) on tumor. Anti-Mouse/Human TYRP1 Antibody (TA99) enhances infiltration of the tumor by CD8+ T cells. Anti-Mouse/Human TYRP1 Antibody (TA99) can be used for the research of melanoma .
|
-
- HY-100155
-
|
|
Sigma Receptor
Apoptosis
Autophagy
|
Cancer
|
|
4-IBP is a selective σ₁ receptor agonist with high affinity for the σ₁ receptor (Ki =1.7 nM) and moderate affinity for the σ₂ receptor (Ki = 25.2 nM). 4-IBP can make cancer cells more sensitive to the cytotoxic effects of pro-apoptotic and pro-autophagic compounds. 4-IBP significantly reduces the migration ability of a variety of cancer cells. 4-IBP is mainly used in glioblastoma, non-small cell lung cancer and prostate cancer research .
|
-
- HY-118147
-
|
|
Fatty Acid Synthase (FASN)
|
Cancer
|
|
ML356 (Compound 16) is an inhibitor for fatty acid synthase (FAS), that inhibits the thioesterase domain of FAS (FAS TE) with an IC50 of 0.334 μM, and blocks the de novo palmitate synthesis in PC-3 cell with an IC50 of 20 μM. ML356 exhibits good membrane permeability, and good stability in human and mouse plasma .
|
-
- HY-42484
-
|
Eribulin intermediate
|
Microtubule/Tubulin
|
Cancer
|
|
ER-076349 (Eribulin intermediate) is an inhibitor of tubulin polymerization, induces G2-M cell cycle arrest, and disrupts mitotic spindles. ER-076349 inhibits cancer cell growth, and inhibits tumor growth in several human tumor xenografts. ER-076349 is an analog of Halichondrin B .
|
-
- HY-117548
-
UNC1062
2 Publications Verification
|
TAM Receptor
Apoptosis
p38 MAPK
ERK
PI3K
Akt
JAK
STAT
|
Cardiovascular Disease
Cancer
|
|
UNC1062 is a highly selective tyrosine kinase (MERTK) inhibitor with an IC50 of 1.1 nM (Morrison Ki = 0.33 nM). UNC1062 exhibits good selectivity for the TAM family (TYRO3 IC50 = 60 nM, AXL IC50 = 85 nM). UNC1062 exhibits significant anti-proliferative effects and induces apoptosis in various cancer models (such as melanoma, gastric cancer, and acute myeloid leukemia). UNC1062 inhibits multiple pathways, including MAPK/ERK, PI3K/AKT and JAK/STAT and affects the motility of head and neck squamous cell carcinoma (HNSCC) cells through the RhoA signaling pathway. UNC1062 inhibits macrophage efferocytosis, and it suitable for research on atherosclerosis .
|
-
- HY-W053583R
-
|
DOTA (Standard)
|
Biochemical Assay Reagents
Reference Standards
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .
|
-
- HY-149380
-
|
|
Raf
|
Cancer
|
|
Vem-L-Cy5 (compound 3)，modified with the NIR fluorophore cyanine-5 (Cy5)，is a Vemurafenib (HY-12057)-based inhibitor of BRAF. Vem-L-Cy5 targets to BRAF V600E，and also inhibits MEK phosphorylation. Vem-L-Cy5 has cell permeability，and inhibits cell growth of many types of cancer .
|
-
- HY-15792
-
|
10,11-(Methylenedioxy)-20(R)-camptothecin
|
Drug Derivative
|
Cancer
|
|
(R)-FL118 (10,11-(Methylenedioxy)-20(R)-camptothecin) is the R-enantiomer of FL118 (HY-12486). (R)-FL118 shows anticancer activity .
|
-
- HY-15217
-
|
|
Haspin Kinase
|
Cancer
|
|
CHR-6494 is a potent inhibitor of haspin, with an IC50 of 2 nM. CHR-6494 inhibits histone H3T3 phosphorylation. CHR-6494 can be used in the research of cancer .
|
-
- HY-P990807
-
|
|
CD1
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD1d Antibody (20H2 (HB323)) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse CD1d. Anti-Mouse CD1d Antibody (20H2 (HB323)) can block CD1d and neutralize invariant natural killer
T (iNKT) cells. Anti-Mouse CD1d Antibody (20H2 (HB323)) can be used for the researches of cancer, infection, inflammation and immunology, such as melanoma, L. monocytogenes infection and arthritis .
|
-
- HY-110382
-
|
c-di-GMP disodium; cyclic diguanylate disodium; 5GP-5GP disodium
|
STING
Endogenous Metabolite
|
Cancer
|
|
Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research .
|
-
- HY-15028
-
|
ATB-346
|
COX
Apoptosis
|
Inflammation/Immunology
|
|
Otenaproxesul (ATB-346), an orally active non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase-1 and 2 (COX-1 and 2). Otenaproxesul possesses antiinflammatory and antinociceptive activities .
|
-
- HY-123009
-
|
|
HIF/HIF Prolyl-Hydroxylase
Histone Acetyltransferase
|
Cancer
|
|
KCN1 is a p300/HIF-1α interaction inhibitor. KCN1 inhibits HIF transcriptional activity by binding to the CH1 domain of p300 and preventing the p300/HIF-1α assembly. KCN1 exerts antitumor activities through cell cycle arrest .
|
-
- HY-107780B
-
|
c-di-GMP diammonium; cyclic diguanylate diammonium; 5GP-5GP diammonium
|
STING
Endogenous Metabolite
|
Cancer
|
|
Cyclic-di-GMP diammonium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP diammonium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP diammonium can be used in cancer research .
|
-
- HY-107780A
-
|
c-di-GMP sodium; cyclic diguanylate sodium; 5GP-5GP sodium
|
STING
Endogenous Metabolite
|
Cancer
|
|
Cyclic-di-GMP sodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP sodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP sodium can be used in cancer research .
|
-
- HY-15028R
-
|
|
COX
Apoptosis
|
Inflammation/Immunology
|
|
Otenaproxesul (Standard) is the analytical standard of Otenaproxesul. This product is intended for research and analytical applications. Otenaproxesul (ATB-346), an orally active non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase-1 and 2 (COX-1 and 2). Otenaproxesul possesses antiinflammatory and antinociceptive activities .
|
-
- HY-107780
-
|
c-di-GMP; cyclic diguanylate; 5GP-5GP
|
STING
Endogenous Metabolite
|
Cancer
|
|
Cyclic-di-GMP is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP can be used in cancer research .
|
-
- HY-131295
-
|
|
MEK
Ligands for Target Protein for PROTAC
|
Cancer
|
|
PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader .
|
-
- HY-103211
-
L748337
1 Publications Verification
|
Adrenergic Receptor
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
L748337 is a potent β3-adrenergic receptor antagonist and displays selectivity over β1 and β2 receptors. The Ki values of L748337 for β3-, β2- and β1-adrenoceptors are 4.0 nM, 204 nM and 390 nM, respectively . L748337 couples predominantly to Gi to activate MAPK signaling and increases phosphorylation of Erk1/2 with pEC50 value of 11.6 . L748337 can be used for the research of cancer, nonalcoholic fatty liver disease (NAFLD), and cardiovascular related diseases .
|
-
- HY-147864
-
|
|
c-Fms
c-Kit
Apoptosis
|
Cancer
|
|
c-Fms-IN-12 (Compound 4g) is an FMS kinase inhibitor. c-Fms-IN-12 can also inhibits c-KIT. c-Fms-IN-12 is a potential broad-spectrum anticancer agent against multiple cancer types. c-Fms-IN-12 induces A549 cell apoptosis .
|
-
- HY-168428
-
|
|
Histone Acetyltransferase
Apoptosis
|
Cancer
|
|
CHI-KAT8i5 is a selective and orally active KAT8 inhibitor with a KD value of 19.72 μM. CHI-KAT8i5 does not bind to other proteins in HAT family (KAT2A, KAT2B, KAT5, and KAT7). CHI-KAT8i5 induces cancer cell apoptosis. CHI-KAT8i5 suppresses esophageal squamous cell carcinoma (ESCC) growth through targeting KAT8/c-Myc signaling pathway .
|
-
- HY-155101
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC50 value and EC50 value is 4.97nM and 2.70 μM for inhibit PD-L1 and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research .
|
-
- HY-124481
-
|
|
COX
Reactive Oxygen Species (ROS)
NO Synthase
Keap1-Nrf2
Heme Oxygenase (HO)
Amyloid-β
Parasite
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Oleocanthal is an orally active phenolic seciridoid compound. Oleocanthal can be extracted from olive oil. Oleocanthal inhibits COX-1 and COX-2, reduces ROS and NO, and upregulates Nrf-2 and HO-1. Oleocanthal reduces Aβ deposition. Oleocanthal exhibits anti-Leishmania activity against promastigotes and amastigotes of L. major, with IC50 values of 18.7 and 87 μg/mL, respectively. Oleocanthal exhibits anticancer activity against colon, breast, liver, and melanoma cancers. Oleocanthal also exhibits anti-inflammatory and neuroprotective properties. Oleocanthal can be used in Alzheimer's disease research .
|
-
- HY-160218
-
|
|
MAP4K
|
Cancer
|
|
HPK1-IN-42 (compound 185) ia a HPK1 inhibitor with the IC50 50 of 0.24 nM .
|
-
- HY-121255
-
|
(R)-Cryptopleurine; NSC 19912
|
TMV
|
Cancer
|
|
(–)-Cryptopleurine is an alkaloid that has been found in Lauraceae and has diverse biological activities. It inhibits the growth of human A375 melanoma, A431 epidermoid carcinoma, A549 lung, MES-SA uterine sarcoma, and MCF-7 breast cancer cells (IC50=3 nM for all).2 (–)-Cryptopleurine inhibits hypoxia-induced gene expression in a hypoxia response element (HRE) reporter assay (IC50=8.7 nM).3 (–)-Cryptopleurine (500 μg/mL) prevents lesion formation in tobacco (N. tabacum) plants infected with tobacco mosaic virus (TMV). It also inhibits protein synthesis by yeast and mammalian ribosomes.
|
-
- HY-P11108
-
|
|
NF-κB
Apoptosis
TNF Receptor
Caspase
|
Inflammation/Immunology
Cancer
|
|
RP-182 is a synthetic immunomodulatory peptide that exerts anti-tumor effects by targeting the mannose receptor CD206 (Kd = 8 μM) on the surface of tumor-associated macrophages (TAMs). RP-182 induces a conformational switch of the CD206 receptor, which activates NF-κB signaling and phagocytosis in CD206 high TAMs. RP-182 has dual function: activation of canonical NF-κB signaling, triggering TNFα secretion and autocrine activation of the TNF receptor 1 (TNFR1), leading to activation of caspase 8, apoptosis, and cell death. RP-182 is used in pancreatic cancer and melanoma research .
|
-
- HY-N7678
-
|
|
Others
|
Cancer
|
|
Gypenoside LXXV, isolated from Gynostemma pentaphyllum, is one of the deglycosylated shapes of ginsenoside Rb1. Gypenoside LXXV significantly reduces cancer cell viability and displays an anti-cancer effect .
|
-
- HY-B0150A
-
|
Niacinamide Hydrochloride; Nicotinic acid amide Hydrochloride
|
Sirtuin
Endogenous Metabolite
HBV
|
Infection
Cancer
|
|
Nicotinamide Hydrochloride is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide Hydrochloride also inhibits SIRT1. Nicotinamide Hydrochloride increases cellular NAD+, ATP, ROS levels. Nicotinamide Hydrochloride inhibits tumor growth and improves survival. Nicotinamide Hydrochloride also has anti-HBV activity .
|
-
- HY-B0150
-
Nicotinamide
Maximum Cited Publications
80 Publications Verification
Niacinamide; Nicotinic acid amide
|
Organoid
Endogenous Metabolite
Sirtuin
HBV
|
Cancer
|
|
Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .
|
-
- HY-16918A
-
|
SBi4211 dimethanesulfonate
|
Others
|
Inflammation/Immunology
Cancer
|
|
Heptamidine dimethanesulfonate (SBi4211 dimethanesulfonate) is a potent Pentamidine-related inhibitor of the calcium-binding protein S100B (Kd=6.9 μM), selectively kills melanoma cells with S100B over those without S100B . Heptamidine is a useful tool for the investigation of Myotonic dystrophy (DM) .
|
-
- HY-16918
-
|
SBi4211
|
Others
|
Inflammation/Immunology
Cancer
|
|
Heptamidine (SBi4211) is a potent Pentamidine-related inhibitor of the calcium-binding protein S100B (Kd=6.9 μM), selectively kills melanoma cells with S100B over those without S100B . Heptamidine is a useful tool for the investigation of Myotonic dystrophy (DM) .
|
-
- HY-175381
-
|
|
PROTACs
Pyroptosis
Reactive Oxygen Species (ROS)
Caspase
|
Cancer
|
|
DeFer-2 is a ferritin PROTAC degrader (Kd = 17.1 μM). DeFer-2 induces ferritin degradation, triggering caspase 3-GSDME-mediated pyroptosis in cancer cells through free iron accumulation and elevated ROS. DeFer-2 significantly inhibits tumor growth and prolongs survival in mice bearing B16F10 subcutaneous tumors. DeFer-2 can be used to study melanoma. (Pink: Oleic acid: HY-N1446, Blue: (S,R,S)-AHPC: HY-125845, Black: γ-Aminobutyric acid: HY-N0067, Blue + Black: (S,R,S)-AHPC-C3-NH2: HY-130711) .
|
-
- HY-N0538
-
|
Xylite
|
Autophagy
Endogenous Metabolite
Bacterial
Atg7
Atg8/LC3
|
Metabolic Disease
Cancer
|
|
Xylitol can be classified as a polyol and sugar alcohol, exhibiting inhibitory activity on cancer cell proliferation. It induces autophagy (Autophagy) and cell death in A549 cells by activating the autophagy signaling pathway, as evidenced by the increased expression of LC3-II and Atg5-Atg12 upon Xylitol treatment. Additionally, Xylitol inhibits acetaldehyde production by Candida species, thereby reducing their carcinogenic potential. In vivo, Xylitol induces alterations in the gut microbiota of mice, which may enhance cholesterol accumulation and upregulate hepatic ChREBP, while also slowing tumor growth in the B16F10 melanoma C57BL/6 mouse model .
|
-
- HY-174468
-
|
|
LYTACs
PD-1/PD-L1
HSP
|
Cancer
|
|
dPDL1-4 is a potent and selective eHSPTAC eHSP90 PD-L1 degrader with DC50s of 7.77 μM and 6.52 μM in HeLa and B16F10 cells. dPDL1-4 bridges eHSP90 with the target protein, inducing lysosomal degradation. dPDL1-4 can degrade PD-L1 significantly and inhibits tumor growth. dPDL1-4 can be used for the study of cervical cancer and melanoma. ((Pink: eHSP90 ligand (HY-174476); Blue: PD-L1 ligand (HY-116274); Black: Linker (HY-W021787); HSP ligand + linker: HY-174799)) .
|
-
- HY-17547
-
|
|
HSP
|
Cancer
|
|
NMS-E973 is a potent and selective inhibitor of HSP90. NMS-E973 binds to the ATP binding site of Hsp90α with a DC50 of <10 nM. NMS-E973 is able to cross the blood-brain barrier (BBB). Antitumor efficacy .
|
-
- HY-168597
-
|
|
FGFR
Apoptosis
VEGFR
|
Cancer
|
|
FGFR1/VEGFR2-IN-3 (Compound 8m) is a dual inhibitor of FGFR1/VEGFR2. FGFR1/VEGFR2-IN-3 exhibits anti-proliferative and anti-migratory activities against cancer cells, and is capable of inducing cell apoptosis .
|
-
- HY-W011209R
-
|
|
Autophagy
Endogenous Metabolite
|
Cancer
|
|
N6-Isopentenyladenosine (Riboprine), an RNA modification found in cytokinins, which regulate plant growth/differentiation, and a subset of tRNAs, where it improves the efficiency and accuracy of translation. N6-Isopentenyladenosine, an end product of the mevalonate pathway, is an autophagy inhibitor with an interesting anti-melanoma activity .
|
-
- HY-W011209
-
|
Riboprine
|
Autophagy
Endogenous Metabolite
|
Cancer
|
|
N6-Isopentenyladenosine (Riboprine), an RNA modification found in cytokinins, which regulate plant growth/differentiation, and a subset of tRNAs, where it improves the efficiency and accuracy of translation. N6-Isopentenyladenosine, an end product of the mevalonate pathway, is an autophagy inhibitor with an interesting anti-melanoma activity .
|
-
- HY-152263
-
|
|
PROTACs
CDK
Apoptosis
|
Cancer
|
|
HEMTAC CDK4/6 degrader 1 is a PROTAC connected by ligands for HSP90 and CDK4/6 with a Kd value of 35.7 μM. HEMTAC CDK4/6 degrader 1 induces CDK4/6 degradation in B16F10 melanoma cells. HEMTAC CDK4/6 degrader 1 arrests cell cycle at G0/G1 phase and induces apoptosis. HEMTAC CDK4/6 degrader 1 can be used in research of cancer . HEMTAC CDK4/6 degrader 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-202699
-
|
|
Ras
Apoptosis
|
Cancer
|
|
SHOC2-RAS PPI-IN-1 (compound 6) is a non-covalent competitive inhibitor targeting the interaction between SHOC2 and RAS proteins. SHOC2-RAS PPI-IN-1 has an IC50 of 0.048 μM and a KD of 0.065 μM for NRAS Q61R. SHOC2-RAS PPI-IN-1 can inhibit the activity of the SMP phosphatase complex, leading to increased CRAF S259 phosphorylation levels, thereby blocking the MAPK signaling pathway (such as reducing the levels of pMEK and pERK), inducing tumor cell cycle arrest and apoptosis. SHOC2-RAS PPI-IN-1 can be used for targeted research on malignant tumors such as melanoma and colorectal cancer with NRAS Q61R mutations .
|
-
- HY-162275
-
|
|
Histone Demethylase
Histone Methyltransferase
STAT
|
Cancer
|
|
JMJD1C-IN-1 is an orally active and selective inhibitor of JMJD1C (IC50 = 0.59 μM, Kd = 1.96 μM). JMJD1C-IN-1 inhibits the binding of JMJD1C to H3K9me2 peptide substrate in the HTRF assay (IC50 = 1.47 μM). JMJD1C-IN-1 disrupts intratumoral regulatory T (Treg) cell fitness by dual mechanisms: promoting H3K9me2 accumulation to downregulate PD1 expression and reducing STAT3 demethylation to enhance STAT3 activation. JMJD1C-IN-1 demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models (MCA205 fibrosarcoma, B16-F10 melanoma, LLC lung cancer, Hepa1-6 hepatocellular carcinoma, CT26 colorectal cancer). JMJD1C-IN-1 can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells .
|
-
- HY-137605
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
WSF1-IN-1 (compound 136), an orally active WSF1 inhibitor, can be used in the study for WSF1 (Wolfram syndrome) related tumors, with IC50 values of 0.33 μM and >27 μM in HepG2 parental and HepG2 WFS1 KO cell lines, respectively .
|
-
- HY-W768347
-
|
Xylite-13C5
|
Isotope-Labeled Compounds
Bacterial
Autophagy
Endogenous Metabolite
Atg8/LC3
Atg7
|
Cancer
|
|
Xylitol- 13C5 (Xylite- 13C5) is the 13C-labeled Xylitol (HY-N0538). Xylitol can be classified as a polyol and sugar alcohol, exhibiting inhibitory activity on cancer cell proliferation. It induces autophagy (Autophagy) and cell death in A549 cells by activating the autophagy signaling pathway, as evidenced by the increased expression of LC3-II and Atg5-Atg12 upon Xylitol treatment. Additionally, Xylitol inhibits acetaldehyde production by Candida species, thereby reducing their carcinogenic potential. In vivo, Xylitol induces alterations in the gut microbiota of mice, which may enhance cholesterol accumulation and upregulate hepatic ChREBP, while also slowing tumor growth in the B16F10 melanoma C57BL/6 mouse model .
|
-
- HY-117991
-
|
|
VEGFR
|
Cancer
|
|
DW10075 is a highly selective and orally active VEGFR inhibitor targeting the VEGF/VEGFR pathway. DW10075 selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3, but has no effect on FGFR and PDGFR. DW10075 inhibits VEGF-induced HUVEC proliferation, migration, and tube formation. And DW10075 inhibits angiogenesis in both the rat aortic ring model and the chick chorionic membrane model. DW10075 also exhibits antiproliferative activity against human cancer cell lines, with IC50s of 2.2 μM and 22.2 μM against U87-MG human glioblastoma cells and A375 melanoma cells, respectively. In the nude mouse U87-MG xenograft tumor model, DW10075 (po) significantly inhibits tumor growth and reduces the expression of CD31 and Ki67 in tumor tissues.
|
-
- HY-P990233
-
|
|
IFNAR
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IFNγR/CD119 Antibody (GR-20) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse IFNγR/CD119.Anti-Mouse IFNγR/CD119 Antibody (GR-20) reacts with the mouse IFNγR (interferon gamma receptor) α chain also known as CD119 and IFNγ receptor 1. Anti-Mouse IFNγR/CD119 Antibody (GR-20) blocks the binding of IFNγ to CD119 therefore inhibiting IFNγ signaling. Anti-Mouse IFNγR/CD119 Antibody (GR-20) can be used for the researches of cancer, infection, inflammation and immunology, such as melanoma and C. trachomatis infected genital tract inflammation .
|
-
- HY-149705
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-7 (compound 74) is an inhibitor of ICMT (IC50=0.015 μM). ICMT-IN-7 dose-dependently induces ICMT accumulation in the cytoplasm of HCT-116 cells and inhibits the proliferation of multiple cancer cell lines expressing K-Ras and N-Ras .
|
-
- HY-155427
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-20 (compound 54) is an inhibitor of ICMT (IC50=0.682 μM) .
|
-
- HY-156500
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-1 (compound 75) is an inhibitor of ICMT (IC50=0.0013 μM). ICMT-IN-1 dose-dependently induces ICMT accumulation in the cytoplasm of HCT-116 cells and inhibits the proliferation of multiple cancer cell lines expressing K-Ras and N-Ras .
|
-
- HY-151409
-
|
|
CDK
|
Cancer
|
|
CDK1-IN-5 (10h) is a selective CDK1 inhibitor with IC50s of 42.19, 188.71 and 354.15 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN-5 inhibits growth of cancer cells by affecting cell cycle. CDK1-IN-5 can be used for the research of cancer .
|
-
- HY-155433
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-30 (compound 67) is an inhibitor of ICMT (IC50=0.27 μM) .
|
-
- HY-157092A
-
|
|
ICMT
|
Cancer
|
|
(S)-ICMT-IN-3 (compound ent 1-27) is an inhibitor of ICMT (IC50=0.23 μM) .
|
-
- HY-158061
-
|
|
Topoisomerase
Apoptosis
|
Cancer
|
|
Topoisomerase II inhibitor 20 (Compound 3e) is a potent topoisomerase II (Topoisomerase II) inhibitor with an IC50 of 0.98 µM. Topoisomerase II inhibitor 20 induces apoptosis and has broad-spectrum anticancer activity .
|
-
- HY-155431
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-28 (compound 65) is an inhibitor of ICMT (IC50=0.008 μM) .
|
-
- HY-157120
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-52 (compound 44) is an inhibitor of ICMT (IC50=0.052 μM) .
|
-
- HY-155419
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-5 (compound 46) is an inhibitor of ICMT (IC50=0.3 μM) .
|
-
- HY-157103
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-34 (compound 39) is an inhibitor of ICMT (IC50=0.17 μM) .
|
-
- HY-157119
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-51 (compound 43) is an inhibitor of ICMT (IC50=0.55 μM) .
|
-
- HY-157095
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-6 (compound 29) is an inhibitor of ICMT (IC50=0.09 μM) .
|
-
- HY-157118
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-50 (compound 3) is an inhibitor of ICMT (IC50=0.31 μM) .
|
-
- HY-155429
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-24 (compound 63) is an inhibitor of ICMT (IC50=0.19 μM) .
|
-
- HY-155424
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-15 (compound 51) is an inhibitor of ICMT (IC50=0.032 μM) .
|
-
- HY-155422
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-13 (compound 49) is an inhibitor of ICMT (IC50=0.47 μM) .
|
-
- HY-157114
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-46 (compound 25) is an inhibitor of ICMT (IC50=0.556 μM) .
|
-
- HY-157105
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-37 (compound 41) is an inhibitor of ICMT (IC50=0.308 μM) .
|
-
- HY-155430
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-27 (compound 64) is an inhibitor of ICMT (IC50=0.1 μM) .
|
-
- HY-157112
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-44 (compound 23) is an inhibitor of ICMT (IC50=0.167 μM) .
|
-
- HY-157092B
-
|
|
ICMT
|
Cancer
|
|
(R)-ICMT-IN-3 (compound ent 2-27) is an inhibitor of ICMT (IC50=0.01 μM) .
|
-
- HY-157104
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-36 (compound 40) is an inhibitor of ICMT (IC50=0.181 μM) .
|
-
- HY-151407
-
|
|
CDK
|
Cancer
|
|
CDK1-IN-3 (8g) is a selective CDK1 inhibitor with IC50s of 36.8, 305.17 and 369.37 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN-3 inhibits the growth of cancer cells by affecting cell cycle. CDK1-IN-3 can be used for the research of cancer .
|
-
- HY-149706
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-12 (compound 78) is an inhibitor of ICMT (IC50=0.42 μM) .
|
-
- HY-157096
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-8 (compound 30) is an inhibitor of ICMT (IC50=0.652 μM) .
|
-
- HY-149707
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-21 (compound 6ag) is an ICMT inhibitor (IC50=8.8 μM), a sulfonamide-modified farnesyl cysteine (SMFC). The farnesyl and carboxylic acid motifs of ICMT-IN-21 are important structures for inhibiting ICMT .
|
-
- HY-155425
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-17 (compound 52) is an inhibitor of ICMT (IC50=0.38 μM) .
|
-
- HY-157102
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-26 (compound 38) is an inhibitor of ICMT (IC50=0.36 μM) .
|
-
- HY-158061A
-
|
|
Topoisomerase
Apoptosis
|
Cancer
|
|
Topoisomerase II inhibitor 20 TFA is a potent topoisomerase II inhibitor with IC50 of 0.98 µM. Topoisomerase II inhibitor 20 TFA can induce apoptosis and has broad-spectrum anticancer activity .
|
-
- HY-157098
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-16 (compound 33) is an inhibitor of ICMT (IC50=0.131 μM) .
|
-
- HY-157109
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-41 (compound 20) is an inhibitor of ICMT (IC50=0.069 μM) .
|
-
- HY-155434
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-31 (compound 68) is an inhibitor of ICMT (IC50=0.0038 μM) .
|
-
- HY-149730
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-54 (compound 7c) is an adamantyl analogue and an ICMT inhibitor (IC50=12.4 μM), which can inhibit ICMT Methylation. ICMT-in-54 inhibits BFC (N-biotinyl-(6-aminohexanoic)-S-farnesyl-L-cysteine) methylation in saccharomyces cerevisiae expressing ICMT, which is an indirect effect of inhibiting ICMT methylation .
|
-
- HY-157099
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-18 (compound 35) is an inhibitor of ICMT (IC50=0.066 μM) .
|
-
- HY-157108
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-40 (compound 19) is an inhibitor of ICMT (IC50=0.031 μM) .
|
-
- HY-155421
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-11 (compound 48) is an inhibitor of ICMT (IC50=0.031 μM) .
|
-
- HY-155432
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-29 (compound 66) is an inhibitor of ICMT (IC50=0.019 μM) .
|
-
- HY-157106
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-38 (compound 42) is an inhibitor of ICMT (IC50=0.049 μM) .
|
-
- HY-157111
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-43 (compound 22) is an inhibitor of ICMT (IC50=0.04 μM) .
|
-
- HY-157107
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-39 (compound 18) is an inhibitor of ICMT (IC50=0.031 μM) .
|
-
- HY-155435
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-32 (compound 70) is an inhibitor of ICMT (IC50=0.777 μM) .
|
-
- HY-157100
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-23 (compound 36) is an inhibitor of ICMT (IC50=0.123 μM) .
|
-
- HY-157097
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-10 (compound 32) is an inhibitor of ICMT (IC50=0.184 μM) .
|
-
- HY-157101
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-25 (compound 37) is an inhibitor of ICMT (IC50=0.025 μM) .
|
-
- HY-149729
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-53 (compound 12) is an ICMT inhibitor (IC50=0.96 μM) with PAMPA permeability and antiproliferative activity. ICMT-IN-53 inhibits the proliferation of MDA-MB-231 and PC3 with IC50s of 5.14 μM and 5.88 μM, respectively .
|
-
- HY-157116
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-48 (compound 1) is an ICMT inhibitor that is competitive (Km=13 μM) for the prenylated methyl acceptor, the first substrate of ICMT. ICMT-IN-48 inhibits ICMT activity with IC50s affected by the concentration of the second substrate S-adenosylmethinine (SAM), and the IC50s are 3.5 μM (1×Km SAM) and 2.3 μM (10×Km SAM), respectively .
|
-
- HY-157113
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-45 (compound 24) is an inhibitor of ICMT (IC50=0.132 μM) .
|
-
- HY-155418
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-2 (compound 45) is an inhibitor of ICMT (IC50=0.168 μM) .
|
-
- HY-155423
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-14 (compound 50) is an inhibitor of ICMT (IC50=0.025 μM) .
|
-
- HY-157115
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-47 (compound 26) is an inhibitor of ICMT (IC50=0.76 μM) .
|
-
- HY-155426
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-19 (compound 53) is an inhibitor of ICMT (IC50=0.026 μM) .
|
-
- HY-155428
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-22 (compound 62) is an inhibitor of ICMT (IC50=0.63 μM) .
|
-
- HY-157117
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-49 (compound 2) is an inhibitor of ICMT (IC50=0.12 μM) .
|
-
- HY-157110
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-42 (compound 21) is an inhibitor of ICMT (IC50=0.054 μM) .
|
-
- HY-155420
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-9 (compound 47) is an inhibitor of ICMT (IC50=0.16 μM) .
|
-
- HY-157092
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-3 (compound 27) is an inhibitor of ICMT (IC50=0.015 μM) .
|
-
- HY-157094
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-4 (compound 28) is an inhibitor of ICMT (IC50=0.27 μM) .
|
-
- HY-151408
-
|
|
CDK
|
Cancer
|
|
CDK1-IN-4 (10d) is a selective CDK1 inhibitor with IC50s of 44.52, 624.93 and 135.22 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN4 inhibits the growth of cancer cells by affecting cell cycle. CDK1-IN-4 can be used for the research of cancer .
|
-
- HY-149709
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-35 (compound 10n) is a FTPA-triazole compound and ICMT inhibitor (IC50=0.8 μM). ICMT-IN-35 is taken up by mammalian cells and can prevent K-Ras membrane localization and induce K-Ras mislocalization. Furthermore, ICMT-IN-35 is selectively cytotoxic against ICMT +/+ MEF cells and has low micromolar activity (IC50=0.8 μM) against metastatic pancreatic cancer cell lines .
|
-
- HY-155436
-
|
|
ICMT
|
Cancer
|
|
ICMT-IN-33 (compound 73) is an inhibitor of ICMT (IC50=0.46 μM) .
|
-
- HY-P990796
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-2 Antibody (S4B6-1) is an anti-mouse IL-2 IgG2a monoclonal antibody. Anti-Mouse IL-2 Antibody (S4B6-1) can reduce CD4 + T cells and increase Tregs. Anti-Mouse IL-2 Antibody (S4B6-1) can induce Th17 cell differentiation. Anti-Mouse IL-2 Antibody (S4B6-1) can be used for research on cancer such as melanoma. The recommend isotype control of Anti-Mouse IL-2 Antibody (S4B6-1): Rat IgG2a kappa, Isotype Control (HY-P990679) .
|
-
- HY-P990131
-
|
|
CD47
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse CD47/IAP IgG2a monoclonal antibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for researches on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis .
|
-
- HY-P990808
-
|
|
Interleukin Related
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) is a rat-derived IgG2b κ type antibody inhibito, targeting to mouse CD122/IL-2Rβ. Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) can block IL-2 and IL-15. Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) can deplete natural killer (NK) cells and NKT cells. Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) can be used for the researches of cancer, infection, inflammation, immunology and metabolic disease, such as melanoma, experimental autoimmune encephalomyelitis (EAE) and diabetes .
|
-
- HY-W015490R
-
|
|
DNA/RNA Synthesis
NF-κB
Monoamine Oxidase
TNF Receptor
Bacterial
|
Infection
Inflammation/Immunology
Cancer
|
|
1,4-Naphthoquinone is an inhibitor with broad-spectrum inhibitory activity targeting DNA polymerase, NF-κB and monoamine oxidase (MAO-A/B), with antibacterial and anti-biofilm efficacy. 1,4-Naphthoquinone is a competitive inhibitor of MAO-B (Ki=1.4 μM) and a non-competitive inhibitor of MAO-A (Ki=7.7 μM). 1,4-Naphthoquinone inhibits DNA polymerase pol α, β, γ, δ, ε, λ with IC50 ranging from 5.57-128 μM. 1,4-Naphthoquinone inhibits tumor cell proliferation, induces apoptosis and necrosis, and has anti-angiogenic and anti-inflammatory activities by inducing oxidative stress, depleting glutathione (GSH), inhibiting DNA polymerase-mediated DNA synthesis and blocking NF-κB nuclear translocation. 1,4-Naphthoquinone can be used in anti-bacterial , anti-tumor and anti-inflammatory studies, including inhibition of melanoma and colon cancer cell growth and endothelial cell function, as well as LPS-induced inflammation models .
|
-
- HY-W015490
-
|
|
DNA/RNA Synthesis
NF-κB
Monoamine Oxidase
TNF Receptor
Bacterial
|
Infection
Inflammation/Immunology
Cancer
|
|
1,4-Naphthoquinone is an inhibitor with broad-spectrum inhibitory activity targeting DNA polymerase, NF-κB and monoamine oxidase (MAO-A/B), with antibacterial and anti-biofilm efficacy. 1,4-Naphthoquinone is a competitive inhibitor of MAO-B (Ki=1.4 μM) and a non-competitive inhibitor of MAO-A (Ki=7.7 μM). 1,4-Naphthoquinone inhibits DNA polymerase pol α, β, γ, δ, ε, λ with IC50 ranging from 5.57-128 μM. 1,4-Naphthoquinone inhibits tumor cell proliferation, induces apoptosis and necrosis, and has anti-angiogenic and anti-inflammatory activities by inducing oxidative stress, depleting glutathione (GSH), inhibiting DNA polymerase-mediated DNA synthesis and blocking NF-κB nuclear translocation. 1,4-Naphthoquinone can be used in anti-bacterial , anti-tumor and anti-inflammatory studies, including inhibition of melanoma and colon cancer cell growth and endothelial cell function, as well as LPS-induced inflammation models .
|
-
- HY-147039
-
|
NKP-1339 free base; IT-139 free base; KP-1339 free base
|
HSP
Autophagy
|
Cancer
|
|
BOLD-100 (NKP-1339; IT-139) free base is a ruthenium-based anticancer agent. BOLD-100 free base also is an inhibitor of stress-induced GRP78 upregulation, disrupting endoplasmic reticulum (ER) homeostasis and inducing ER stress and unfolded protein response (UPR). BOLD-100 free base interferes with the complex interplay between ER-stress response, lysosome dynamics, and autophagy execution .
|
-
- HY-16350
-
|
NKP-1339; IT-139; KP-1339
|
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
BOLD-100 (NKP-1339; IT-139) is the first-in-class ruthenium-based anticancer agent in development against solid cancer with limited side effects. BOLD-100 induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. BOLD-100 has a high tumor targeting potential, strongly binds to serum proteins such as albumin and transferrin and activates in the reductive tumor milieu .
|
-
- HY-P990144
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) is an anti-mouse/human VLA-4/CD49d IgG2b monoclonal antibody. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can reduce VLA-4 positive cells. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can inhibit the migration of Tc1 cells to tumors. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) inhibits the retention of leukemia cells in the spleen and bone marrow by blocking VLA-4. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can be used for research on inflammation conditions and cancer such as experimental autoimmune encephalomyelitis (EAE), melanoma and leukemia .
|
-
- HY-W015490S
-
|
|
Isotope-Labeled Compounds
DNA/RNA Synthesis
NF-κB
Monoamine Oxidase
TNF Receptor
Bacterial
|
Infection
Inflammation/Immunology
Cancer
|
|
1,4-Naphthoquinone-d6 is the deuterium labeled 1,4-Naphthoquinone. 1,4-Naphthoquinone is an inhibitor with broad-spectrum inhibitory activity targeting DNA polymerase, NF-κB and monoamine oxidase (MAO-A/B), with antibacterial and anti-biofilm efficacy. 1,4-Naphthoquinone is a competitive inhibitor of MAO-B (Ki=1.4 μM) and a non-competitive inhibitor of MAO-A (Ki=7.7 μM). 1,4-Naphthoquinone inhibits DNA polymerase pol α, β, γ, δ, ε, λ with IC50 ranging from 5.57-128 μM. 1,4-Naphthoquinone inhibits tumor cell proliferation, induces apoptosis and necrosis, and has anti-angiogenic and anti-inflammatory activities by inducing oxidative stress, depleting glutathione (GSH), inhibiting DNA polymerase-mediated DNA synthesis and blocking NF-κB nuclear translocation. 1,4-Naphthoquinone can be used in anti-bacterial , anti-tumor and anti-inflammatory studies, including inhibition of melanoma and colon cancer cell growth and endothelial cell function, as well as LPS-induced inflammation models .
|
-
- HY-169021
-
|
|
JNK
|
Cancer
|
|
JNK-1-IN-3 (Compound 9e) is an inhibitor of JNK1 that downregulates JNK1 gene expression and inhibits the protein levels of its phosphorylated form, concurrently reducing the expression of its downstream targets, c-Jun and c-Fos, in tumors while restoring p53 activity. JNK-1-IN-3 exhibits broad-spectrum antiproliferative activity, particularly with high inhibitory activity against renal and breast cancer cell lines, demonstrating both in vivo and in vitro anticancer activity .
|
-
- HY-13594
-
|
Ce6
|
Bcl-2 Family
Caspase
PARP
Apoptosis
Fluorescent Dye
|
Infection
Cancer
|
|
Chlorin e6 is a photosensitizer and has strong absorption peaks at wavelength of 402 and 662 nm, as well as exhibiting intense fluorescence at 668 nm. Chlorin e6 has antimicrobial efficacy and anticancer activity. Chlorin e6 induces cell apoptosis via caspase-3 activation and can be used for the research of cancer .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-15150G
-
|
R428 (GMP); BGB324 (GMP)
|
Fluorescent Dye
|
|
Bemcentinib (R428) GMP is Bemcentinib (HY-15150) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy.Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .
|
| Cat. No. |
Product Name |
Type |
-
- HY-108775A
-
|
Sodium hyposulfite (99%, water≤1.0%)
|
Buffer Reagents
|
|
Sodium thiosulfate is an antioxidant. Sodium thiosulfate inhibits the expression of p-GSK-3β and β-catenin proteins, reduces IL-1β, COX-2, and Iba-1, and inhibits NFκB activation. Sodium thiosulfate promotes angiogenesis, inhibits inflammation, and improves acute lung injury. Sodium thiosulfate also exhibits anti-cancer activity against melanoma. Sodium thiosulfate also exerts renal protective effects. Sodium thiosulfate can be used in the research of osteoarthritis, brain inflammation, cancer (such as breast cancer, melanoma), and kidney disease .
|
-
- HY-W053583
-
|
DOTA
|
Biochemical Assay Reagents
|
|
Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .
|
-
- HY-15150G
-
|
R428 (GMP); BGB324 (GMP)
|
Biochemical Assay Reagents
|
|
Bemcentinib (R428) GMP is Bemcentinib (HY-15150) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy.Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .
|
-
- HY-W053583R
-
|
DOTA (Standard)
|
Biochemical Assay Reagents
|
|
Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1585
-
|
Hgp100 (25-33)
|
MHC
|
Cancer
|
|
Gp100 (25-33), human (Hgp100 (25-33)) is the amino acids 25-33 fragment of the human melanoma antigen. Gp100 (25-33), human is a 9-amino acid (AA) epitope restricted by MHC class I H-2D b and recognized by the T cells. Gp100 (25-33), human has immunogenicity and induces specific T cells. Gp100 (25-33), human can be used for the cancer research, such as melanoma .
|
-
- HY-P1585A
-
|
Hgp100 (25-33) TFA
|
MHC
|
Cancer
|
|
Gp100 (25-33), human TFA (Hgp100 (25-33) (TFA)) is the amino acids 25-33 fragment of the human melanoma antigen. Gp100 (25-33), human TFA is a 9-amino acid (AA) epitope restricted by MHC class I H-2D b and recognized by the T cells. Gp100 (25-33), human TFA has immunogenicity and induces specific T cells. Gp100 (25-33), human TFA can be used for the cancer research, such as melanoma .
|
-
- HY-N2466
-
|
MT-I; [Nle4,D-Phe7]-α-MSH
|
Melanocortin Receptor
|
Neurological Disease
Cancer
|
|
Melanotan I is a potent non-selective melanocortin receptor (MCR) agonist. Melanotan I is a synthetic analogue of α-melanocyte stimulating hormone (α-MSH) that stimulates melanogenesis. Melanotan I can induce skin tanning by mimicking the actions of a-MSH on the melanocortin type 1 receptors (MC1R) of melanocytes. Melanotan I can be used for the research of sun-induced skin cancer, melanoma, inflammation and male erectile dysfunction .
|
-
- HY-P3742
-
|
|
Tyrosinase
|
Cancer
|
|
Tyrosinase (192-200), human mouse is a nonapeptide. Tyrosinase (192-200), human mouse can be recognized by cytolytic T cell (CTL) on the HLA-B44 molecule. Tyrosinase (192-200), human mouse can be used in research of melanoma associated cancers .
|
-
- HY-P11110
-
|
|
PD-1/PD-L1
|
Cancer
|
|
RK-10 is a PD-L1 binding peptide. RK-10 conjugated with Cy5 (HY-D0821) or Biotin (HY-B0511) can used to detect PD-L1 expressing tumors with flow cytometry or immunohistochemistry. RK-10 can be used for cancers like NSCLC, breast cancer, squamous cell carcinoma and melanoma detection research .
|
-
- HY-P11018
-
|
|
Peptide-Drug Conjugates (PDCs)
Ephrin Receptor
|
Cancer
|
|
(123B9)2-L2-PTX is an EphA2-agonistic peptide-drug conjugate (PDC). (123B9)2-L2-PTX consists of a dimeric 123B9 (HY-P10579) and Paclitaxel (HY-B0015). (123B9)2-L2-PTX significantly reduces circulating tumor cells and inhibits lung tumor metastasis in breast-cancer-Metastasis mice model. (123B9)2-L2-PTX can be used for cancers research, such as melanomas and ovarian and breast cancers .
|
-
- HY-P10010
-
|
|
Galectin
|
Cancer
|
|
DB21, Galectin-1 Antagonist is a dibenzofuran conjugated peptidomimetic that acts as an allosteric inhibitor of galectin-1 (GAL1)binding to cell surface glycans. DB21, Galectin-1 Antagonis increases inhibition of angiogenesis and tumour growth in melanoma, lung adenocarcinoma and ovarian cancer models .
|
-
- HY-P11011
-
|
Pep R54; CXCR4 antagonist peptide 19
|
CXCR
|
Cancer
|
|
Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting CXCR4 with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC50=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .
|
-
- HY-P11108
-
|
|
NF-κB
Apoptosis
TNF Receptor
Caspase
|
Inflammation/Immunology
Cancer
|
|
RP-182 is a synthetic immunomodulatory peptide that exerts anti-tumor effects by targeting the mannose receptor CD206 (Kd = 8 μM) on the surface of tumor-associated macrophages (TAMs). RP-182 induces a conformational switch of the CD206 receptor, which activates NF-κB signaling and phagocytosis in CD206 high TAMs. RP-182 has dual function: activation of canonical NF-κB signaling, triggering TNFα secretion and autocrine activation of the TNF receptor 1 (TNFR1), leading to activation of caspase 8, apoptosis, and cell death. RP-182 is used in pancreatic cancer and melanoma research .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99202
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research .
|
-
- HY-P99205
-
|
|
ADC Antibody
|
Cancer
|
|
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
|
-
- HY-P990106
-
|
|
VEGFR
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse VEGFR-2 Antibody (DC101) is a rat anti-mouse VEGFR2 monoclonal antibody. Anti-Mouse VEGFR-2 Antibody (DC101) inhibits tumor angiogenesis by blocking the binding of VEGF and VEGFR2. Anti-Mouse VEGFR-2 Antibody (DC101) promotes immune cell infiltration and induces tumor cell apoptosis. Anti-Mouse VEGFR-2 Antibody (DC101) can be used for researches on various types of cancer such as melanoma, lung cancer and breast cancer .
|
-
- HY-P990805
-
|
|
HSP
|
Metabolic Disease
Cancer
|
|
Anti-Human/Mouse GRP78 Antibody (C38) is a kind of mouse IgG2b antibody inhibitor, targeting to GRP78. Anti-Human/Mouse GRP78 Antibody (C38) inhibits RhoA, ROCK and AKT activation. Anti-Human/Mouse GRP78 Antibody (C38) can be used for the researches of cancer and metabolic disease, such as melanoma and diabetes .
|
-
- HY-P99132
-
|
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonal antibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances T cell function by increasing the ratio of CD8 + T cells to regulatory T cells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma .
|
-
- HY-P990273
-
|
|
CD38
ERK
CD1
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD38 Antibody (NIMR5) is an anti-mouse CD38 IgG2a monoclonal antibody. Anti-Mouse CD38 Antibody (NIMR5) can activate the ERK signaling pathway and promote cell apoptosis. Anti-Mouse CD38 Antibody (NIMR5) can restore T cell function. Anti-Mouse CD38 Antibody (NIMR5) upregulates the expression of CD1d protein and enhances spleen cell proliferation, dendritic cell (DC) and natural killer T cell (NKT) expansion. Anti-Mouse CD38 Antibody (NIMR5) can be used for researches on cancer and immunology such as melanoma and colon cancer .
|
-
- HY-P9978
-
|
JS-001
|
PD-1/PD-L1
|
Cancer
|
|
Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .
|
-
- HY-P991425
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
AT-1413 is a human monoclonal antibody (mAb) targeting CD43. AT-1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. AT-1413 has antitumor activity in AML mouse models. AT-1413 can be used in Acute myeloid leukaemia, Breast cancer, Malignant melanoma and Myelodysplastic syndromes research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991585
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
MORAb-028 is a humanized IgG1 monoclonal antibody inhibitor targeting GD2. MORAb-028 has a potent antitumor activity and kills GD2-expressing target cells via complement-mediated cytotoxicity (CDC). MORAb-028 significantly inhibits tumor growth in EL-4-luc xenograft mice model. MORAb-028 can be used for melanoma cancer research .
|
-
- HY-P991566
-
|
|
CTLA-4
|
Cancer
|
|
KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .
|
-
- HY-P99049
-
|
APX005M; APX005M; EPI-0050
|
TNF Receptor
|
Inflammation/Immunology
|
|
Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma .
|
-
- HY-P9986
-
|
MTIG-7192A; RG-6058
|
CD28
|
Cancer
|
|
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma .
|
-
- HY-P99101
-
|
AEX-4089; MGC026 antibody
|
ADC Antibody
|
Cancer
|
|
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .
|
-
- HY-P990861
-
|
|
Transmembrane Glycoprotein
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-CD4 Antibody (OKT-4) is a kind of mouse IgG2b κ chimeric antibody inhibitor, targeting to human CD4. Anti-CD4 Antibody (OKT-4) can deplete T cells. Anti-CD4 Antibody (OKT-4) can be used for the researches of cancer, infection and immunology, such as melanoma and adenovirus infection .
|
-
- HY-P991243
-
|
|
EGFR
PI3K
Akt
|
Cancer
|
|
MP-RM-1 is a selective murine monoclonal antibody inhibitor targeting human epidermal growth factor receptor 3 (ErbB-3). MP-RM-1 blocks the activation of ErbB-3 induced by neuregulin 1 (NRG-1β) and promotes the internalization and degradation of ErbB-3, inhibiting downstream signaling pathways such as PI3K-Akt. MP-RM-1 is promising for research of ErbB-3 highly expressed solid tumors such as breast cancer, melanoma, and prostate cancer .
|
-
- HY-P99291
-
|
LM609; MEDI-522
|
Integrin
Apoptosis
Akt
|
Cancer
|
|
Etaracizumab (LM 609) is an αvβ3 integrin IgG mAb. Etaracizumab is developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofαvβ3-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990165
-
|
|
RANKL/RANK
E1/E2/E3 Enzyme
NF-κB
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse RANKL/CD254 Antibody (IK22/5) is an anti-mouse RANKL/CD254 IgG2a monoclonal antibody. Anti-Mouse RANKL/CD254 Antibody (IK22/5) inhibits osteoclast formation and activity by specifically blocking the binding of RANKL and RANK. Anti-Mouse RANKL/CD254 Antibody (IK22/5) can inhibit the expression of MuRF1/Trogin-1 and activation of NF-κB. Anti-Mouse RANKL/CD254 Antibody (IK22/5) can be used for research on cancer such as melanoma or colon cancer and osteoporosis .
|
-
- HY-P99781
-
|
MLN-1202
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab can also improve synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990149
-
|
|
Tyrosinase
|
Cancer
|
|
Anti-Mouse/Human TYRP1 Antibody (TA99) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse/human TYRP1. Anti-Mouse/Human TYRP1 Antibody (TA99) binds to Tyrp1 (tyrosinase related protein-1) on tumor. Anti-Mouse/Human TYRP1 Antibody (TA99) enhances infiltration of the tumor by CD8+ T cells. Anti-Mouse/Human TYRP1 Antibody (TA99) can be used for the research of melanoma .
|
-
- HY-P990807
-
|
|
CD1
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD1d Antibody (20H2 (HB323)) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse CD1d. Anti-Mouse CD1d Antibody (20H2 (HB323)) can block CD1d and neutralize invariant natural killer
T (iNKT) cells. Anti-Mouse CD1d Antibody (20H2 (HB323)) can be used for the researches of cancer, infection, inflammation and immunology, such as melanoma, L. monocytogenes infection and arthritis .
|
-
- HY-P990233
-
|
|
IFNAR
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IFNγR/CD119 Antibody (GR-20) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse IFNγR/CD119.Anti-Mouse IFNγR/CD119 Antibody (GR-20) reacts with the mouse IFNγR (interferon gamma receptor) α chain also known as CD119 and IFNγ receptor 1. Anti-Mouse IFNγR/CD119 Antibody (GR-20) blocks the binding of IFNγ to CD119 therefore inhibiting IFNγ signaling. Anti-Mouse IFNγR/CD119 Antibody (GR-20) can be used for the researches of cancer, infection, inflammation and immunology, such as melanoma and C. trachomatis infected genital tract inflammation .
|
-
- HY-P990796
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-2 Antibody (S4B6-1) is an anti-mouse IL-2 IgG2a monoclonal antibody. Anti-Mouse IL-2 Antibody (S4B6-1) can reduce CD4 + T cells and increase Tregs. Anti-Mouse IL-2 Antibody (S4B6-1) can induce Th17 cell differentiation. Anti-Mouse IL-2 Antibody (S4B6-1) can be used for research on cancer such as melanoma. The recommend isotype control of Anti-Mouse IL-2 Antibody (S4B6-1): Rat IgG2a kappa, Isotype Control (HY-P990679) .
|
-
- HY-P990131
-
|
|
CD47
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse CD47/IAP IgG2a monoclonal antibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for researches on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis .
|
-
- HY-P990808
-
|
|
Interleukin Related
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) is a rat-derived IgG2b κ type antibody inhibito, targeting to mouse CD122/IL-2Rβ. Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) can block IL-2 and IL-15. Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) can deplete natural killer (NK) cells and NKT cells. Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) can be used for the researches of cancer, infection, inflammation, immunology and metabolic disease, such as melanoma, experimental autoimmune encephalomyelitis (EAE) and diabetes .
|
-
- HY-P990144
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) is an anti-mouse/human VLA-4/CD49d IgG2b monoclonal antibody. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can reduce VLA-4 positive cells. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can inhibit the migration of Tc1 cells to tumors. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) inhibits the retention of leukemia cells in the spleen and bone marrow by blocking VLA-4. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can be used for research on inflammation conditions and cancer such as experimental autoimmune encephalomyelitis (EAE), melanoma and leukemia .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-113107
-
-
-
- HY-111604
-
|
|
Marine natural products
Source classification
|
Others
|
|
Turbinaric acid is a kind of secosqualene carboxylic acid. Turbinaric acid exhibits cytotoxicity against mouse melanoma cells and human colon cancer cells. Turbinaric acid can be used as a chemical marker for T. conoides. Turbinaric acid can be used for research on melanoma and colon cancer .
|
-
-
- HY-N0610A
-
-
-
- HY-N0308
-
-
-
- HY-111898
-
|
|
Source classification
Plants
|
Others
|
|
Epirosmanol is a nature diterpene lactone from S. officinalis. Epirosmanol shows anti-cancer activity and inhibits melanin biosynthesis against melanoma cells. Epirosmanol also exhibits DPPH radical scavenging activity .
|
-
-
- HY-129144
-
-
-
- HY-138098
-
-
-
- HY-102010
-
-
-
- HY-N0610AR
-
-
-
- HY-120607
-
-
-
- HY-113107R
-
-
-
- HY-N0308R
-
-
-
- HY-N11644
-
|
|
Triterpenes
Microorganisms
Terpenoids
Source classification
|
Others
|
|
Lanosta-7,9(11),24-trien-3α-hydroxy-26-oic acid, also known as ganoderic acid 24. Lanosta-7,9(11),24-trien-3α-hydroxy-26-oic acid shows high cytotoxicity against cancer cells, such as human lung cancer cells CH27, melanoma cells M21, and oral cancer cells HSC-3 .
|
-
-
- HY-N0421
-
-
-
- HY-N0288
-
-
-
- HY-N12834
-
|
|
Apocynaceae
Polysaccharides
Source classification
Plants
Saccharides
Urceola rosea (Hook. & Arn.) D. J. Middleton
|
Others
|
|
Ecdysoside B (compound 6b) is a pregnanoside compound isolated from the plant Ecdysanthera rosea. Ecdysoside B and its derivatives and isomers shows anticancer, immunosuppressive and anti-inflammatory activities. Ecdysoside B shows cytotoxicity to a variety of human tumor cell lines, including PANC-1 (human pancreatic cancer cells), A375 (human melanoma cells) and U87 (brain glioma U87 cells). Ecdysoside B can be used for research in the areas of cancer, immunomodulation and anti-inflammato .
|
-
-
- HY-N8207
-
-
-
- HY-N0421R
-
|
Cinobufagine (Standard)
|
Animals
Source classification
Steroids
|
Reference Standards
Apoptosis
|
|
Cinobufagin (Standard) is the analytical standard of Cinobufagin. This product is intended for research and analytical applications. Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models .
|
-
-
- HY-N0288R
-
-
-
- HY-117037
-
|
|
Ardisia crenata Sims
Ketones, Aldehydes, Acids
Source classification
Plants
Myrsinaceae
|
Apoptosis
ERK
|
|
FR900359 is a depsipeptide selective inhibitor of Gαq/11/14 in mammalia, can inhibits ERK pathway. FR900359 suppresses the proliferation of melanoma cells and decreases of blood pressure. FR900359 also protected against airway hyperreactivity in murine models of allergen sensitization in Ovalbumins(HY-W250978)–induced sensitization model of asthma. FR900359 can be used for cancer and cardiovascular disease research .
|
-
-
- HY-W587938
-
|
(+)-γ-Eudesmol
|
Terpenoids
Sesquiterpenes
Source classification
Rutaceae
Plants
Amyris balsamifera L.
|
Apoptosis
|
|
γ-Eudesmol ((+)-γ-Eudesmol) is a mitochondrial-mediated apoptosis inducer. γ-Eudesmol binds mitochondrial membrane proteins, triggering depolarization of mitochondrial membrane potential and activating caspase cascades. γ-Eudesmol demonstrates cytotoxicity against multiple tumor cell lines (e.g., HepG2, B16-F10) with IC50 values ranging from 8.86-15.15 μg/mL. γ-Eudesmol is promising for research of cancers, such as hepatocellular carcinoma and melanoma .
|
-
-
- HY-110382
-
-
-
- HY-107780B
-
-
-
- HY-107780A
-
-
-
- HY-107780
-
-
-
- HY-124481
-
-
-
- HY-N7678
-
-
-
- HY-B0150A
-
-
-
- HY-B0150
-
-
-
- HY-N0538
-
-
-
- HY-W011209R
-
-
-
- HY-W011209
-
-
| Cat. No. |
Compare |
Product Name |
Species |
Source |
Compare Products
|
| Products |
|
| Cat. No. |
|
| Species |
|
| Source |
|
| Tag |
|
| Accession |
|
| Gene ID |
|
| Molecular Weight |
|
| Purity |
|
| Endotoxin Level |
|
| Biological Activity |
|
| Appearance |
|
| Formulation |
|
| Storage & Stability |
|
| Shipping |
|
| Free Sample |
Yes
No
|
| Size |
* This product has been "discontinued".
Optimized version of product available:
|
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-N0610AS
-
|
|
|
Cinnamic acid-d6 is the deuterium labeled Cinnamic acid. Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
|
-
-
- HY-N0610AS2
-
|
|
|
Cinnamic acid- 13C3 (3-Phenylacrylic acid- 13C3) is the 13C labeled Cinnamic acid (HY-N0610A). Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells .
|
-
-
- HY-W015490S
-
|
|
|
1,4-Naphthoquinone-d6 is the deuterium labeled 1,4-Naphthoquinone. 1,4-Naphthoquinone is an inhibitor with broad-spectrum inhibitory activity targeting DNA polymerase, NF-κB and monoamine oxidase (MAO-A/B), with antibacterial and anti-biofilm efficacy. 1,4-Naphthoquinone is a competitive inhibitor of MAO-B (Ki=1.4 μM) and a non-competitive inhibitor of MAO-A (Ki=7.7 μM). 1,4-Naphthoquinone inhibits DNA polymerase pol α, β, γ, δ, ε, λ with IC50 ranging from 5.57-128 μM. 1,4-Naphthoquinone inhibits tumor cell proliferation, induces apoptosis and necrosis, and has anti-angiogenic and anti-inflammatory activities by inducing oxidative stress, depleting glutathione (GSH), inhibiting DNA polymerase-mediated DNA synthesis and blocking NF-κB nuclear translocation. 1,4-Naphthoquinone can be used in anti-bacterial , anti-tumor and anti-inflammatory studies, including inhibition of melanoma and colon cancer cell growth and endothelial cell function, as well as LPS-induced inflammation models .
|
-
-
- HY-W747797
-
|
|
|
Cinobufagine-d3 is the deuterium labeled Cinobufagin (HY-N0421). Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models .
|
-
-
- HY-W768347
-
|
|
|
Xylitol- 13C5 (Xylite- 13C5) is the 13C-labeled Xylitol (HY-N0538). Xylitol can be classified as a polyol and sugar alcohol, exhibiting inhibitory activity on cancer cell proliferation. It induces autophagy (Autophagy) and cell death in A549 cells by activating the autophagy signaling pathway, as evidenced by the increased expression of LC3-II and Atg5-Atg12 upon Xylitol treatment. Additionally, Xylitol inhibits acetaldehyde production by Candida species, thereby reducing their carcinogenic potential. In vivo, Xylitol induces alterations in the gut microbiota of mice, which may enhance cholesterol accumulation and upregulate hepatic ChREBP, while also slowing tumor growth in the B16F10 melanoma C57BL/6 mouse model .
|
-
| Cat. No. |
Compare |
Product Name |
Application |
Reactivity |
Compare Products
|
| Products |
|
| Cat. No. |
|
| Host |
|
| Reactivity |
|
| Application |
|
Dilution
Ratio |
|
| Molecular Weight |
|
| Conjugation |
|
| Clonality |
|
| Immunogen |
|
| Appearance |
|
| Isotype |
|
| Gene ID |
|
| SwissProt ID |
|
| Purity |
|
| Formulation |
|
| Free Sample |
Yes
No
|
| Size |
* This product has been "discontinued".
Optimized version of product available:
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-146245C
-
|
CpG 1826 sodium
|
|
CpG ODNs
|
|
ODN 1826 sodium is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 sodium induces NO and iNOS production and enhances Apoptosis. ODN 1826 sodium enhances immune surveillance. ODN 1826 sodium increases aortic atherosclerotic plaque size. ODN 1826 sodium has antitumor activity against lung cancer, glioma and melanoma .
|
-
- HY-146245
-
|
CpG 1826
|
|
CpG ODNs
|
|
ODN 1826 is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 induces NO and iNOS production and enhances Apoptosis. ODN 1826 enhances immune surveillance. ODN 1826 increases aortic atherosclerotic plaque size. ODN 1826 has antitumor activity against lung cancer, glioma and melanoma .
|
-
- HY-N0538
-
|
Xylite
|
|
Fillers
|
|
Xylitol can be classified as a polyol and sugar alcohol, exhibiting inhibitory activity on cancer cell proliferation. It induces autophagy (Autophagy) and cell death in A549 cells by activating the autophagy signaling pathway, as evidenced by the increased expression of LC3-II and Atg5-Atg12 upon Xylitol treatment. Additionally, Xylitol inhibits acetaldehyde production by Candida species, thereby reducing their carcinogenic potential. In vivo, Xylitol induces alterations in the gut microbiota of mice, which may enhance cholesterol accumulation and upregulate hepatic ChREBP, while also slowing tumor growth in the B16F10 melanoma C57BL/6 mouse model .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
2](http://file.medchemexpress.eu/product_pic/hy-176859.gif)
